User login
Now Insured, Patient Wants to “Get Checked Out”
ANSWER
There are three findings on this ECG: unusual P waves consistent with a possible ectopic atrial rhythm, a prolonged QT interval, and T-wave abnormalities in the lateral leads.
Note that the P waves are negative in leads I and II, as well as in all chest leads. This is highly suggestive of an ectopic atrial rhythm originating low in the atria, conducting retrograde into the atria, and overriding the sinoatrial node. Limb lead reversal would result in negative P waves in lead I, but not in other leads.
A prolonged QT interval is determined by consulting any of the standard charts that correlate maximum heart rates with QT intervals and gender. In men, the QT interval is considered “prolonged” when it exceeds 440 ms, unless the heart rate is extremely slow.
Finally, T-wave inversions are present in the lateral leads (V5, V6). Although this may be an indication of lateral ischemia, there is no clinical correlation in this patient.
ANSWER
There are three findings on this ECG: unusual P waves consistent with a possible ectopic atrial rhythm, a prolonged QT interval, and T-wave abnormalities in the lateral leads.
Note that the P waves are negative in leads I and II, as well as in all chest leads. This is highly suggestive of an ectopic atrial rhythm originating low in the atria, conducting retrograde into the atria, and overriding the sinoatrial node. Limb lead reversal would result in negative P waves in lead I, but not in other leads.
A prolonged QT interval is determined by consulting any of the standard charts that correlate maximum heart rates with QT intervals and gender. In men, the QT interval is considered “prolonged” when it exceeds 440 ms, unless the heart rate is extremely slow.
Finally, T-wave inversions are present in the lateral leads (V5, V6). Although this may be an indication of lateral ischemia, there is no clinical correlation in this patient.
ANSWER
There are three findings on this ECG: unusual P waves consistent with a possible ectopic atrial rhythm, a prolonged QT interval, and T-wave abnormalities in the lateral leads.
Note that the P waves are negative in leads I and II, as well as in all chest leads. This is highly suggestive of an ectopic atrial rhythm originating low in the atria, conducting retrograde into the atria, and overriding the sinoatrial node. Limb lead reversal would result in negative P waves in lead I, but not in other leads.
A prolonged QT interval is determined by consulting any of the standard charts that correlate maximum heart rates with QT intervals and gender. In men, the QT interval is considered “prolonged” when it exceeds 440 ms, unless the heart rate is extremely slow.
Finally, T-wave inversions are present in the lateral leads (V5, V6). Although this may be an indication of lateral ischemia, there is no clinical correlation in this patient.
A 37-year-old man presents to your office to establish care. After being unemployed for two years, he recently obtained a position with a local manufacturing company and, as a result, has health benefits. He wants to “get checked out.” He has not seen a health care provider since having his tonsils removed at age 14. He says he is rarely ill, aside from an occasional cold. Besides the tonsillectomy, medical history is positive for a right clavicular fracture at age 6 and a left inguinal hernia repair at age 9. He had chickenpox and recalls that his immunizations were up to date until he graduated high school. His only medication is ibuprofen as needed for aches and pains. He has no known drug allergies. He uses two herbal supplements, fenugreek seed and horny goat weed, daily. He admits to recreational marijuana use. Family history is remarkable for coronary artery disease (father), diabetes (mother), and depression (sister). He consumes one six-pack of beer weekly and has smoked one pack of cigarettes per day for the past 23 years. He isn’t interested in quitting smoking. The patient is divorced, without children. He has been collecting unemployment since his last position was terminated due to budget constraints. A 20-point comprehensive review of systems is negative, with the exception of occasional palpitations and a productive morning smoker’s cough that quickly resolves. He states he’s “as healthy as a horse.” The physical exam reveals a thin, healthy-appearing middle-aged male. He is 72 in tall and weighs 167 lb. His blood pressure is 108/66 mm Hg; pulse, 70 beats/min and regular; respiratory rate, 14 breaths/min-1; and temperature, 98.4°F. The head, eyes, ears, nose, and throat (HEENT) exam is remarkable for poor dentition, with multiple caries readily visible. The tonsils are absent. Coarse expiratory crackles are present in both bases and clear with vigorous coughing. The abdominal exam is positive for a well-healed scar in the left inguinal crease. The remainder of the physical exam is normal. As part of a new patient visit, a chest x-ray and ECG are obtained. The ECG shows the following: a ventricular rate of 69 beats/min; PR interval, 178 ms; QRS duration, 90ms; QT/QTc interval, 442/473 ms; P axis, 231°; R axis, 84°; and T axis, 93°. What is your interpretation of this ECG?
A Purplish Rash on the Instep
ANSWER
The correct answer is lichen planus (choice “d”), an inflammatory condition marked by pathognomic histologic changes such as those described. Hardly on the tip of most primary care providers’ tongues, lichen planus is nonetheless quite commonly occuring.
Tinea pedis (choice “a”) certainly belongs in the differential, but it would be unusual in a woman of this age. The biopsy effectively ruled it out, as it did psoriasis (choice “b”) and contact dermatitis (choice “c”).
DISCUSSION
Lichen planus (LP) is the prototypical lichenoid interface dermatitis; an inflammatory infiltrate erases the normally well-defined dermoepidermal junction, replacing it with a jagged “sawtooth” band of lymphocytes. In the process, the cells it kills off (keratinocytes) collect at this interface and are incorporated as necrotic keratinocytes into the papillary dermis.
Classically, the recognition of LP is taught with “The Ps.” LP is said to be:
• Papular
• Planar
• Purple
• Polygonal
• Pruritic
• Plaquish
• Penile
• Puzzling
The word “puzzling” may sound nebulous, but it is actually quite useful for dermatology providers. It comes into play whenever a condition stumps us—as in, “What in the world is this?” This puzzlement causes us to at least consider LP.
LP is often papular, and these papules often have flat (planar) tops. The purple color is more striking in lighter-skinned patients. (Almost all inflammatory conditions are more difficult to diagnose in those with darker skin.) More typically, LP lesions are multi-angular or polygonal, often plaquish, and almost invariably pruritic.
LP is common on the legs and/or trunk, favoring the sacral area. It can affect the scalp (being in the differential for hair loss), can cause nail dystrophy, and is relatively common in the mouth, where it presents as a lacy, reticular, slightly erosive process, usually affecting the buccal mucosae. It may be found on the penis, where it is usually confined to the distal shaft and proximal coronal areas.
Like many otherwise benign conditions, LP can present with bullae. In anterior tibial areas, especially on darker-skinned persons, it can be remarkably hypertrophic.
The cause is usually unknown, although certain drugs—especially the antimalarials, gold salts, and penicillamine—have been known to cause LP-like eruptions. It’s been my observation that flares of LP are prompted by stress (certainly present in this patient’s case). LP may have a connection to hepatitis, although no convincing connection has been established.
TREATMENT
This patient’s condition was treated with topical class I corticosteroid ointment (halobetasol). For her, having a certain diagnosis was almost as important as successful treatment.
ANSWER
The correct answer is lichen planus (choice “d”), an inflammatory condition marked by pathognomic histologic changes such as those described. Hardly on the tip of most primary care providers’ tongues, lichen planus is nonetheless quite commonly occuring.
Tinea pedis (choice “a”) certainly belongs in the differential, but it would be unusual in a woman of this age. The biopsy effectively ruled it out, as it did psoriasis (choice “b”) and contact dermatitis (choice “c”).
DISCUSSION
Lichen planus (LP) is the prototypical lichenoid interface dermatitis; an inflammatory infiltrate erases the normally well-defined dermoepidermal junction, replacing it with a jagged “sawtooth” band of lymphocytes. In the process, the cells it kills off (keratinocytes) collect at this interface and are incorporated as necrotic keratinocytes into the papillary dermis.
Classically, the recognition of LP is taught with “The Ps.” LP is said to be:
• Papular
• Planar
• Purple
• Polygonal
• Pruritic
• Plaquish
• Penile
• Puzzling
The word “puzzling” may sound nebulous, but it is actually quite useful for dermatology providers. It comes into play whenever a condition stumps us—as in, “What in the world is this?” This puzzlement causes us to at least consider LP.
LP is often papular, and these papules often have flat (planar) tops. The purple color is more striking in lighter-skinned patients. (Almost all inflammatory conditions are more difficult to diagnose in those with darker skin.) More typically, LP lesions are multi-angular or polygonal, often plaquish, and almost invariably pruritic.
LP is common on the legs and/or trunk, favoring the sacral area. It can affect the scalp (being in the differential for hair loss), can cause nail dystrophy, and is relatively common in the mouth, where it presents as a lacy, reticular, slightly erosive process, usually affecting the buccal mucosae. It may be found on the penis, where it is usually confined to the distal shaft and proximal coronal areas.
Like many otherwise benign conditions, LP can present with bullae. In anterior tibial areas, especially on darker-skinned persons, it can be remarkably hypertrophic.
The cause is usually unknown, although certain drugs—especially the antimalarials, gold salts, and penicillamine—have been known to cause LP-like eruptions. It’s been my observation that flares of LP are prompted by stress (certainly present in this patient’s case). LP may have a connection to hepatitis, although no convincing connection has been established.
TREATMENT
This patient’s condition was treated with topical class I corticosteroid ointment (halobetasol). For her, having a certain diagnosis was almost as important as successful treatment.
ANSWER
The correct answer is lichen planus (choice “d”), an inflammatory condition marked by pathognomic histologic changes such as those described. Hardly on the tip of most primary care providers’ tongues, lichen planus is nonetheless quite commonly occuring.
Tinea pedis (choice “a”) certainly belongs in the differential, but it would be unusual in a woman of this age. The biopsy effectively ruled it out, as it did psoriasis (choice “b”) and contact dermatitis (choice “c”).
DISCUSSION
Lichen planus (LP) is the prototypical lichenoid interface dermatitis; an inflammatory infiltrate erases the normally well-defined dermoepidermal junction, replacing it with a jagged “sawtooth” band of lymphocytes. In the process, the cells it kills off (keratinocytes) collect at this interface and are incorporated as necrotic keratinocytes into the papillary dermis.
Classically, the recognition of LP is taught with “The Ps.” LP is said to be:
• Papular
• Planar
• Purple
• Polygonal
• Pruritic
• Plaquish
• Penile
• Puzzling
The word “puzzling” may sound nebulous, but it is actually quite useful for dermatology providers. It comes into play whenever a condition stumps us—as in, “What in the world is this?” This puzzlement causes us to at least consider LP.
LP is often papular, and these papules often have flat (planar) tops. The purple color is more striking in lighter-skinned patients. (Almost all inflammatory conditions are more difficult to diagnose in those with darker skin.) More typically, LP lesions are multi-angular or polygonal, often plaquish, and almost invariably pruritic.
LP is common on the legs and/or trunk, favoring the sacral area. It can affect the scalp (being in the differential for hair loss), can cause nail dystrophy, and is relatively common in the mouth, where it presents as a lacy, reticular, slightly erosive process, usually affecting the buccal mucosae. It may be found on the penis, where it is usually confined to the distal shaft and proximal coronal areas.
Like many otherwise benign conditions, LP can present with bullae. In anterior tibial areas, especially on darker-skinned persons, it can be remarkably hypertrophic.
The cause is usually unknown, although certain drugs—especially the antimalarials, gold salts, and penicillamine—have been known to cause LP-like eruptions. It’s been my observation that flares of LP are prompted by stress (certainly present in this patient’s case). LP may have a connection to hepatitis, although no convincing connection has been established.
TREATMENT
This patient’s condition was treated with topical class I corticosteroid ointment (halobetasol). For her, having a certain diagnosis was almost as important as successful treatment.
Several months ago, an itchy rash appeared on the foot of this 61-year-old African-American woman. She tried using a variety of OTC and prescription products, including tolnaftate cream, hydrocortisone 1% cream, and triamcinolone cream, but the rash persisted. She reports that the triamcinolone cream did relieve the itching for a few minutes after application, but the symptoms always returned. The rash has gradually grown. The patient, a retired schoolteacher, denies any other skin problems. She does have several relatively minor health problems, including hypertension (well controlled with metoprolol) and mild reactive airway disease (related to a 20-year history of smoking). The rash manifested around the time she was forced to retire in an unforeseen downsizing effort by her school district. As a result, she lost her health care coverage and could not afford private insurance for herself and her husband (neither of whom are old enough to qualify for Medicare). The rash, which covers a roughly 12 × 8–cm area, begins on her left instep and spills onto the lower ankle. It is quite dark, as would be expected in a person with type V skin, but there is a slightly purplish tinge to it. The surface of the affected area is a bit shiny and atrophic, and the margins are well defined and annular. There is almost no scaling, and the rest of the skin on her feet and legs is well within normal limits. A 4-mm punch biopsy is performed on the lesion. The pathology report shows obliteration of the dermoepidermal junction by a bandlike lymphocytic infiltrate in the papillary dermis, associated with vacuolar changes and the accumulation of necrotic keratinocytes in the basal layer.
Renal risk stratification with the new oral anticoagulants
To the Editor: I read with interest the review of the new oral anticoagulants by Fawole et al1 and agree with their comments on the prevention of bleeding and the importance of monitoring renal function in managing patients on the new classes of oral anticoagulants. However, no specifics were given on how to proceed. Thus, I recommend that renal risk stratification be done before and 1 week after starting these new drugs.
Originally, the US Food and Drug Administration approved dabigatran (Pradaxa) at a dose of 150 mg orally twice daily in patients with a creatinine clearance of 15 to 30 mL/min/1.73 m2. This dosing corresponded to the estimated glomerular filtration rate (eGFR) in patients with stage 4 chronic kidney disease, but this dosing is contraindicated in other guidelines worldwide (Canada, Europe, the United Kingdom, Japan, Australia, and New Zealand).2 Not unexpectedly, 3,781 serious adverse effects were noted in the 2011 US postmarketing experience with dabigatran. These included death (542 cases), hemorrhage (2,367 cases), acute renal failure (291 cases), stroke (644 cases), and suspected liver failure (15 cases).3 Thirteen months after dabigatran’s approval in the United States, Boehringer Ingelheim changed the dosage and product guidelines.2–4 The new dosage4 is 75 mg twice daily for patients with a creatinine clearance of 15 to 30 mL/min/1.73 m2.
Therefore, I suggest a nephrologic “way out”5 when using the new oral anticoagulants to avoid the problems with dabigatran noted above.
First, if these drugs are to be used in nonvalvular atrial fibrillation, risk factors should be determined using the CHADS2 or the CHADS2-VASc score. Special attention should be given to patients age 75 and older, women, and patients with a history of stroke, transient ischemic attack, or systemic embolism. All of these have been noted to be major risk factors.6,7
Second, renal risk stratification8 should be done using a comprehensive metabolic panel before and 1 week after starting new oral anticoagulants, or if there is a change in the patient’s clinical condition. Most US laboratories now provide an eGFR and the stage of chronic kidney disease.3,5 For example (Table 1), if dabigatran is used, one should follow current dosing guidelines for chronic kidney disease stages 1 through 3, ie, 150 mg twice daily. If stage 4 chronic kidney disease is detected (creatinine clearance 15–29 mL/min/1.73 m2), the updated recommended dosage is 75 mg twice daily. If stage 5 is noted (eGFR ≤ 15 mL/min/1.73 m2), dabigatran is not indicated. Similar steps can be done using current guidelines for the other new oral anticoagulants.
This simple renal risk stratification guideline should help avoid some of the problems noted in the dabigatran postmarketing experience, which were aggravated by the lack of approval of a 110-mg dose and by misleading advertising, claiming that no blood monitoring was required.2–5 Thus, the new oral anticoagulants should be a welcome addition to our armamentarium in patients who need them, and we hope to avoid the risks, morbidity, mortality, and expense of trying to reverse adverse effects.
- Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants, dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013, 80:443–451.
- Pazmiño PA. Dabigatran associated acute renal failure (DAARF). El Paso Physician 2011; 34:7–9.
- Pazmiño PA. Adverse effects of dabigatran (Letter). Ann Intern Med 2012; 157:916.
- Pradaxa (prescribing information). Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals 2011.
- Pazmiño PA. Dabigatran: a nephrological way out. Am J Med 2013; 126;e21–e22.
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263–272.
- Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705–711.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1–S266.
To the Editor: I read with interest the review of the new oral anticoagulants by Fawole et al1 and agree with their comments on the prevention of bleeding and the importance of monitoring renal function in managing patients on the new classes of oral anticoagulants. However, no specifics were given on how to proceed. Thus, I recommend that renal risk stratification be done before and 1 week after starting these new drugs.
Originally, the US Food and Drug Administration approved dabigatran (Pradaxa) at a dose of 150 mg orally twice daily in patients with a creatinine clearance of 15 to 30 mL/min/1.73 m2. This dosing corresponded to the estimated glomerular filtration rate (eGFR) in patients with stage 4 chronic kidney disease, but this dosing is contraindicated in other guidelines worldwide (Canada, Europe, the United Kingdom, Japan, Australia, and New Zealand).2 Not unexpectedly, 3,781 serious adverse effects were noted in the 2011 US postmarketing experience with dabigatran. These included death (542 cases), hemorrhage (2,367 cases), acute renal failure (291 cases), stroke (644 cases), and suspected liver failure (15 cases).3 Thirteen months after dabigatran’s approval in the United States, Boehringer Ingelheim changed the dosage and product guidelines.2–4 The new dosage4 is 75 mg twice daily for patients with a creatinine clearance of 15 to 30 mL/min/1.73 m2.
Therefore, I suggest a nephrologic “way out”5 when using the new oral anticoagulants to avoid the problems with dabigatran noted above.
First, if these drugs are to be used in nonvalvular atrial fibrillation, risk factors should be determined using the CHADS2 or the CHADS2-VASc score. Special attention should be given to patients age 75 and older, women, and patients with a history of stroke, transient ischemic attack, or systemic embolism. All of these have been noted to be major risk factors.6,7
Second, renal risk stratification8 should be done using a comprehensive metabolic panel before and 1 week after starting new oral anticoagulants, or if there is a change in the patient’s clinical condition. Most US laboratories now provide an eGFR and the stage of chronic kidney disease.3,5 For example (Table 1), if dabigatran is used, one should follow current dosing guidelines for chronic kidney disease stages 1 through 3, ie, 150 mg twice daily. If stage 4 chronic kidney disease is detected (creatinine clearance 15–29 mL/min/1.73 m2), the updated recommended dosage is 75 mg twice daily. If stage 5 is noted (eGFR ≤ 15 mL/min/1.73 m2), dabigatran is not indicated. Similar steps can be done using current guidelines for the other new oral anticoagulants.
This simple renal risk stratification guideline should help avoid some of the problems noted in the dabigatran postmarketing experience, which were aggravated by the lack of approval of a 110-mg dose and by misleading advertising, claiming that no blood monitoring was required.2–5 Thus, the new oral anticoagulants should be a welcome addition to our armamentarium in patients who need them, and we hope to avoid the risks, morbidity, mortality, and expense of trying to reverse adverse effects.
To the Editor: I read with interest the review of the new oral anticoagulants by Fawole et al1 and agree with their comments on the prevention of bleeding and the importance of monitoring renal function in managing patients on the new classes of oral anticoagulants. However, no specifics were given on how to proceed. Thus, I recommend that renal risk stratification be done before and 1 week after starting these new drugs.
Originally, the US Food and Drug Administration approved dabigatran (Pradaxa) at a dose of 150 mg orally twice daily in patients with a creatinine clearance of 15 to 30 mL/min/1.73 m2. This dosing corresponded to the estimated glomerular filtration rate (eGFR) in patients with stage 4 chronic kidney disease, but this dosing is contraindicated in other guidelines worldwide (Canada, Europe, the United Kingdom, Japan, Australia, and New Zealand).2 Not unexpectedly, 3,781 serious adverse effects were noted in the 2011 US postmarketing experience with dabigatran. These included death (542 cases), hemorrhage (2,367 cases), acute renal failure (291 cases), stroke (644 cases), and suspected liver failure (15 cases).3 Thirteen months after dabigatran’s approval in the United States, Boehringer Ingelheim changed the dosage and product guidelines.2–4 The new dosage4 is 75 mg twice daily for patients with a creatinine clearance of 15 to 30 mL/min/1.73 m2.
Therefore, I suggest a nephrologic “way out”5 when using the new oral anticoagulants to avoid the problems with dabigatran noted above.
First, if these drugs are to be used in nonvalvular atrial fibrillation, risk factors should be determined using the CHADS2 or the CHADS2-VASc score. Special attention should be given to patients age 75 and older, women, and patients with a history of stroke, transient ischemic attack, or systemic embolism. All of these have been noted to be major risk factors.6,7
Second, renal risk stratification8 should be done using a comprehensive metabolic panel before and 1 week after starting new oral anticoagulants, or if there is a change in the patient’s clinical condition. Most US laboratories now provide an eGFR and the stage of chronic kidney disease.3,5 For example (Table 1), if dabigatran is used, one should follow current dosing guidelines for chronic kidney disease stages 1 through 3, ie, 150 mg twice daily. If stage 4 chronic kidney disease is detected (creatinine clearance 15–29 mL/min/1.73 m2), the updated recommended dosage is 75 mg twice daily. If stage 5 is noted (eGFR ≤ 15 mL/min/1.73 m2), dabigatran is not indicated. Similar steps can be done using current guidelines for the other new oral anticoagulants.
This simple renal risk stratification guideline should help avoid some of the problems noted in the dabigatran postmarketing experience, which were aggravated by the lack of approval of a 110-mg dose and by misleading advertising, claiming that no blood monitoring was required.2–5 Thus, the new oral anticoagulants should be a welcome addition to our armamentarium in patients who need them, and we hope to avoid the risks, morbidity, mortality, and expense of trying to reverse adverse effects.
- Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants, dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013, 80:443–451.
- Pazmiño PA. Dabigatran associated acute renal failure (DAARF). El Paso Physician 2011; 34:7–9.
- Pazmiño PA. Adverse effects of dabigatran (Letter). Ann Intern Med 2012; 157:916.
- Pradaxa (prescribing information). Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals 2011.
- Pazmiño PA. Dabigatran: a nephrological way out. Am J Med 2013; 126;e21–e22.
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263–272.
- Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705–711.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1–S266.
- Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants, dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med 2013, 80:443–451.
- Pazmiño PA. Dabigatran associated acute renal failure (DAARF). El Paso Physician 2011; 34:7–9.
- Pazmiño PA. Adverse effects of dabigatran (Letter). Ann Intern Med 2012; 157:916.
- Pradaxa (prescribing information). Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals 2011.
- Pazmiño PA. Dabigatran: a nephrological way out. Am J Med 2013; 126;e21–e22.
- Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137:263–272.
- Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol 2009; 20:705–711.
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39(suppl 1):S1–S266.
In reply: Renal risk stratification with the new oral anticoagulants
In Reply: We agree with the comments of Dr. Pazmiño regarding specifics of renal risk stratification in patients taking the new oral anticoagulants. In order to reduce the bleeding risks associated with these agents, they should be prescribed on the basis of the individual patient’s clinical characteristics. We did not discuss this since the focus of our article was management of bleeding that resulted from use of these drugs. We appreciate the recommendations of Dr. Pazmiño.
In Reply: We agree with the comments of Dr. Pazmiño regarding specifics of renal risk stratification in patients taking the new oral anticoagulants. In order to reduce the bleeding risks associated with these agents, they should be prescribed on the basis of the individual patient’s clinical characteristics. We did not discuss this since the focus of our article was management of bleeding that resulted from use of these drugs. We appreciate the recommendations of Dr. Pazmiño.
In Reply: We agree with the comments of Dr. Pazmiño regarding specifics of renal risk stratification in patients taking the new oral anticoagulants. In order to reduce the bleeding risks associated with these agents, they should be prescribed on the basis of the individual patient’s clinical characteristics. We did not discuss this since the focus of our article was management of bleeding that resulted from use of these drugs. We appreciate the recommendations of Dr. Pazmiño.
Not all joint pain is arthritis
To the Editor: I was somewhat confused by the Clinical Picture case in the May 2013 issue.1 The caption for Figure 1 stated that the MRI showed erosions and marrow edema, which were “asymmetrical compared with the other wrist, a finding highly suggestive of rheumatoid arthritis.” However, rheumatoid arthritis is generally considered to be symmetrical.2 Was this a typographical error, or did I miss a crucial concept somewhere?
- Kochhar GS, Rizk M, Patil DT. Not all joint pain is arthritis. Cleve Clin J Med 2013; 80:272–273.
- Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology 2002; 41:246–252.
To the Editor: I was somewhat confused by the Clinical Picture case in the May 2013 issue.1 The caption for Figure 1 stated that the MRI showed erosions and marrow edema, which were “asymmetrical compared with the other wrist, a finding highly suggestive of rheumatoid arthritis.” However, rheumatoid arthritis is generally considered to be symmetrical.2 Was this a typographical error, or did I miss a crucial concept somewhere?
To the Editor: I was somewhat confused by the Clinical Picture case in the May 2013 issue.1 The caption for Figure 1 stated that the MRI showed erosions and marrow edema, which were “asymmetrical compared with the other wrist, a finding highly suggestive of rheumatoid arthritis.” However, rheumatoid arthritis is generally considered to be symmetrical.2 Was this a typographical error, or did I miss a crucial concept somewhere?
- Kochhar GS, Rizk M, Patil DT. Not all joint pain is arthritis. Cleve Clin J Med 2013; 80:272–273.
- Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology 2002; 41:246–252.
- Kochhar GS, Rizk M, Patil DT. Not all joint pain is arthritis. Cleve Clin J Med 2013; 80:272–273.
- Bukhari M, Lunt M, Harrison BJ, Scott DG, Symmons DP, Silman AJ. Erosions in inflammatory polyarthritis are symmetrical regardless of rheumatoid factor status: results from a primary care-based inception cohort of patients. Rheumatology 2002; 41:246–252.
In reply: Not all joint pain is arthritis
In Reply: We apologize for the confusion. We wanted to convey that, in that patient at that time, synovitis with erosions and edema indicating inflammation (greater on the right than on the left left) was suggestive of rheumatoid arthritis despite the asymmetry seen (findings greater in the right wrist than in the left). Given the patient’s clinical findings at that time and the above imaging findings, the initial diagnosis of rheumatoid arthritis was correct. But since the patient was not responding to therapy and since the abdominal pain was worsening, we probed further. Subsequently, the patient was diagnosed with Whipple disease. The fact that inflammatory arthritis can occur in other conditions that are not rheumatologic is a primary reason we found this case worth sharing.
In Reply: We apologize for the confusion. We wanted to convey that, in that patient at that time, synovitis with erosions and edema indicating inflammation (greater on the right than on the left left) was suggestive of rheumatoid arthritis despite the asymmetry seen (findings greater in the right wrist than in the left). Given the patient’s clinical findings at that time and the above imaging findings, the initial diagnosis of rheumatoid arthritis was correct. But since the patient was not responding to therapy and since the abdominal pain was worsening, we probed further. Subsequently, the patient was diagnosed with Whipple disease. The fact that inflammatory arthritis can occur in other conditions that are not rheumatologic is a primary reason we found this case worth sharing.
In Reply: We apologize for the confusion. We wanted to convey that, in that patient at that time, synovitis with erosions and edema indicating inflammation (greater on the right than on the left left) was suggestive of rheumatoid arthritis despite the asymmetry seen (findings greater in the right wrist than in the left). Given the patient’s clinical findings at that time and the above imaging findings, the initial diagnosis of rheumatoid arthritis was correct. But since the patient was not responding to therapy and since the abdominal pain was worsening, we probed further. Subsequently, the patient was diagnosed with Whipple disease. The fact that inflammatory arthritis can occur in other conditions that are not rheumatologic is a primary reason we found this case worth sharing.
Ponatinib sales and marketing suspended
After follow-up data from the phase 2 PACE trial revealed that ponatinib-treated patients experienced an increase in arterial and venous thrombotic events, the FDA decided to investigate the drug’s safety.
The agency placed current ponatinib trials on partial clinical hold and asked the drug’s makers, Ariad Pharmaceuticals, to end the phase 3 EPIC trial.
Now, the FDA has asked Ariad to temporarily suspend marketing and sales of ponatinib while the agency further evaluates the drug.
Ponatinib is approved in the US and the European Union to treat adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant to or intolerant of other tyrosine kinase inhibitors.
Recommendations for ponatinib use
Until its safety evaluation is complete, the FDA is recommending that healthcare professionals reconsider the use of ponatinib.
For patients who are taking ponatinib but not responding, immediately discontinue their treatment and discuss alternative treatment options.
For patients who are currently taking ponatinib and responding, determine whether the potential benefits of the therapy outweigh the risks. If they do, these patients should be treated under a single-patient investigational new drug (IND) application or expanded access registry program while the FDA’s safety investigation continues.
Do not start treating new patients with ponatinib unless no other treatment options are available and all other available therapies have failed. Patients who meet these criteria can be considered for treatment under an IND or expanded access registry program.
For more information on obtaining access to treatment for your patient under an IND, please refer to the following website: Physician Request for an Individual Patient IND under Expanded Access for Non-emergency or Emergency Use.
Ponatinib safety data
Thus far, the FDA’s investigation of ponatinib has revealed an increased frequency of arterial and venous thrombotic events since the drug was approved in December 2012.
In clinical trials conducted before the drug’s approval, serious arterial thrombosis occurred in 8% of ponatinib-treated patients, and venous thromboembolism occurred in 3%. In the most recent clinical trial data, at least 20% of all participants treated with ponatinib have developed thrombosis or arteriosclerosis.
Serious adverse vascular events have occurred in about 24% of patients in the phase 2 trial of ponatinib (median treatment duration of 1.3 years) and about 48% of patients in the phase 1 trial (median treatment duration of 2.7 years).
These included fatal and life-threatening heart attack, stroke, loss of blood flow to the extremities resulting in tissue death, and severe narrowing of blood vessels in the extremities, heart, and brain requiring urgent surgical procedures to restore blood flow.
In the phase 2 trial, adverse events affecting the blood vessels that supply the heart, brain, and extremities were observed in 12%, 6%, and 8% of patients, respectively. Patients with and without cardiovascular risk factors, including patients in their 20s, have experienced these events.
Serious adverse reactions involving the eyes, which led to blindness or blurred vision, occurred in ponatinib-treated patients. High blood pressure occurred in 67% of patients treated with ponatinib in the trials. Heart failure, including fatalities, occurred in 8% of patients who received the drug.
In some patients, fatal and serious adverse events have occurred as early as 2 weeks after starting ponatinib therapy.
The phase 1 and 2 trials did not include a control group, so it is not possible to determine the relationship of these adverse events to ponatinib. However, the increasing rate and pattern of the events strongly suggests that many are drug-related, according to the FDA.
The agency said it cannot currently identify a dose level or exposure duration of ponatinib that is safe. Prior to the issues with adverse events, the recommended dose of ponatinib was a 45 mg tablet taken once daily.
The FDA said it plans to continue its investigation and will notify healthcare professionals and patients as more information becomes available.
After follow-up data from the phase 2 PACE trial revealed that ponatinib-treated patients experienced an increase in arterial and venous thrombotic events, the FDA decided to investigate the drug’s safety.
The agency placed current ponatinib trials on partial clinical hold and asked the drug’s makers, Ariad Pharmaceuticals, to end the phase 3 EPIC trial.
Now, the FDA has asked Ariad to temporarily suspend marketing and sales of ponatinib while the agency further evaluates the drug.
Ponatinib is approved in the US and the European Union to treat adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant to or intolerant of other tyrosine kinase inhibitors.
Recommendations for ponatinib use
Until its safety evaluation is complete, the FDA is recommending that healthcare professionals reconsider the use of ponatinib.
For patients who are taking ponatinib but not responding, immediately discontinue their treatment and discuss alternative treatment options.
For patients who are currently taking ponatinib and responding, determine whether the potential benefits of the therapy outweigh the risks. If they do, these patients should be treated under a single-patient investigational new drug (IND) application or expanded access registry program while the FDA’s safety investigation continues.
Do not start treating new patients with ponatinib unless no other treatment options are available and all other available therapies have failed. Patients who meet these criteria can be considered for treatment under an IND or expanded access registry program.
For more information on obtaining access to treatment for your patient under an IND, please refer to the following website: Physician Request for an Individual Patient IND under Expanded Access for Non-emergency or Emergency Use.
Ponatinib safety data
Thus far, the FDA’s investigation of ponatinib has revealed an increased frequency of arterial and venous thrombotic events since the drug was approved in December 2012.
In clinical trials conducted before the drug’s approval, serious arterial thrombosis occurred in 8% of ponatinib-treated patients, and venous thromboembolism occurred in 3%. In the most recent clinical trial data, at least 20% of all participants treated with ponatinib have developed thrombosis or arteriosclerosis.
Serious adverse vascular events have occurred in about 24% of patients in the phase 2 trial of ponatinib (median treatment duration of 1.3 years) and about 48% of patients in the phase 1 trial (median treatment duration of 2.7 years).
These included fatal and life-threatening heart attack, stroke, loss of blood flow to the extremities resulting in tissue death, and severe narrowing of blood vessels in the extremities, heart, and brain requiring urgent surgical procedures to restore blood flow.
In the phase 2 trial, adverse events affecting the blood vessels that supply the heart, brain, and extremities were observed in 12%, 6%, and 8% of patients, respectively. Patients with and without cardiovascular risk factors, including patients in their 20s, have experienced these events.
Serious adverse reactions involving the eyes, which led to blindness or blurred vision, occurred in ponatinib-treated patients. High blood pressure occurred in 67% of patients treated with ponatinib in the trials. Heart failure, including fatalities, occurred in 8% of patients who received the drug.
In some patients, fatal and serious adverse events have occurred as early as 2 weeks after starting ponatinib therapy.
The phase 1 and 2 trials did not include a control group, so it is not possible to determine the relationship of these adverse events to ponatinib. However, the increasing rate and pattern of the events strongly suggests that many are drug-related, according to the FDA.
The agency said it cannot currently identify a dose level or exposure duration of ponatinib that is safe. Prior to the issues with adverse events, the recommended dose of ponatinib was a 45 mg tablet taken once daily.
The FDA said it plans to continue its investigation and will notify healthcare professionals and patients as more information becomes available.
After follow-up data from the phase 2 PACE trial revealed that ponatinib-treated patients experienced an increase in arterial and venous thrombotic events, the FDA decided to investigate the drug’s safety.
The agency placed current ponatinib trials on partial clinical hold and asked the drug’s makers, Ariad Pharmaceuticals, to end the phase 3 EPIC trial.
Now, the FDA has asked Ariad to temporarily suspend marketing and sales of ponatinib while the agency further evaluates the drug.
Ponatinib is approved in the US and the European Union to treat adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant to or intolerant of other tyrosine kinase inhibitors.
Recommendations for ponatinib use
Until its safety evaluation is complete, the FDA is recommending that healthcare professionals reconsider the use of ponatinib.
For patients who are taking ponatinib but not responding, immediately discontinue their treatment and discuss alternative treatment options.
For patients who are currently taking ponatinib and responding, determine whether the potential benefits of the therapy outweigh the risks. If they do, these patients should be treated under a single-patient investigational new drug (IND) application or expanded access registry program while the FDA’s safety investigation continues.
Do not start treating new patients with ponatinib unless no other treatment options are available and all other available therapies have failed. Patients who meet these criteria can be considered for treatment under an IND or expanded access registry program.
For more information on obtaining access to treatment for your patient under an IND, please refer to the following website: Physician Request for an Individual Patient IND under Expanded Access for Non-emergency or Emergency Use.
Ponatinib safety data
Thus far, the FDA’s investigation of ponatinib has revealed an increased frequency of arterial and venous thrombotic events since the drug was approved in December 2012.
In clinical trials conducted before the drug’s approval, serious arterial thrombosis occurred in 8% of ponatinib-treated patients, and venous thromboembolism occurred in 3%. In the most recent clinical trial data, at least 20% of all participants treated with ponatinib have developed thrombosis or arteriosclerosis.
Serious adverse vascular events have occurred in about 24% of patients in the phase 2 trial of ponatinib (median treatment duration of 1.3 years) and about 48% of patients in the phase 1 trial (median treatment duration of 2.7 years).
These included fatal and life-threatening heart attack, stroke, loss of blood flow to the extremities resulting in tissue death, and severe narrowing of blood vessels in the extremities, heart, and brain requiring urgent surgical procedures to restore blood flow.
In the phase 2 trial, adverse events affecting the blood vessels that supply the heart, brain, and extremities were observed in 12%, 6%, and 8% of patients, respectively. Patients with and without cardiovascular risk factors, including patients in their 20s, have experienced these events.
Serious adverse reactions involving the eyes, which led to blindness or blurred vision, occurred in ponatinib-treated patients. High blood pressure occurred in 67% of patients treated with ponatinib in the trials. Heart failure, including fatalities, occurred in 8% of patients who received the drug.
In some patients, fatal and serious adverse events have occurred as early as 2 weeks after starting ponatinib therapy.
The phase 1 and 2 trials did not include a control group, so it is not possible to determine the relationship of these adverse events to ponatinib. However, the increasing rate and pattern of the events strongly suggests that many are drug-related, according to the FDA.
The agency said it cannot currently identify a dose level or exposure duration of ponatinib that is safe. Prior to the issues with adverse events, the recommended dose of ponatinib was a 45 mg tablet taken once daily.
The FDA said it plans to continue its investigation and will notify healthcare professionals and patients as more information becomes available.
Hospitalist‐Run Postdischarge Clinic
Currently, healthcare systems rarely provide ideal transitions of care for discharged patients,[1] resulting in fragmented care,[2, 3, 4, 5] significant patient uncertainty about how to manage at home,[6, 7] and frequent adverse events.[8, 9] These factors are so commonly experienced by discharged patients that they are recognizable as a postdischarge syndrome.[10]
One element important for reducing the postdischarge risk of adverse events is provision of adequate follow‐up.[11, 12] However, supplying this care is challenging in the modern era, and it will become progressively more difficult to achieve. In 2004, 50% of readmitted Medicare fee‐for‐service patients had no postdischarge visit within 30 days of their discharge,[9] likely due in part to difficulty arranging such care. Changes in insurance coverage and demographics are expected to result in more than 100 million newly insured patients by 2019, yet the primary‐care workforce is projected to begin shrinking by 2016.[13, 14] In the increasingly uncommon situation that a primary‐care clinician is available promptly after discharge, information transfer is often inadequate[4, 15, 16, 17] and can be exacerbated by the growing discontinuity between inpatient and outpatient care.[2, 3, 4] Efforts to increase the supply of primary‐care clinicians and thereby improve early access to postdischarge care are important for the future, but hospitals, particularly those penalized for high risk‐adjusted readmission rates, are seeking novel solutions now.
One increasingly common innovation is to extend the role of inpatient providers (usually hospitalists) into the postdischarge period.[18] Preliminary evidence suggests improved continuity[19] and access[20] achieved by providing this care may decrease postdischarge adverse events,[19, 20, 21] though evidence is conflicting.[22]
As a closed, multilevel healthcare system, the Denver VA Medical Center is uniquely positioned to evaluate the influence of alternative postdischarge‐care strategies on subsequent adverse events. Discharged patients are seen in a well‐established hospitalist‐run postdischarge clinic (PDC), a robust urgent‐care system (UC), or by a large primary‐care provider (PCP) practice. The purpose of this study was to evaluate whether patients seen in a hospitalist‐run PDC have reduced adverse outcomes in the 30 days following hospital discharge compared with follow‐up with the patient's PCP or in an UC clinic.
METHODS
Patients
This was a retrospective cohort study of consecutive adult patients discharged from the general medical services of the Denver VA Medical Center after a nonelective admission between January 2005 and August 2012. This time range was chosen because all 3 clinics were fully operational during this period. The Denver VA Medical Center is an academically‐affiliated 128‐bed hospital that provides a full range of tertiary services. All medical patients, including intensive care unit (ICU) patients, are cared for on general medical teams by University of Colorado housestaff with hospitalists or subspecialty attendings. Patients who lived in the Denver metropolitan area, were discharged home, and who followed up with a PCP, UC clinic, or PDC within 30 days of discharge were included. Patients discharged to subacute facilities, hospice, or this tends to be capitalized as a special program at our VA were excluded. For patients with multiple admissions, only the first was included.
Clinics
Primary Care
Primary‐care clinics in the VA system are organized into Patient‐Aligned Care Teams (PACTs) and are available for appointments 5 days per week. Patients discharged from the medical service who have PCPs are called within 48 hours of discharge by PACT nurses to evaluate their postdischarge state. Primary‐care physicians could be resident housestaff or ambulatory attending physicians. Seventy‐two percent of patients seen at the Denver VA have an assigned PCP.
Urgent Care
The Office‐based Medical Team provides UC and short‐term regular appointments for recently discharged medical patients or patients who require frequent follow‐up (such as those that require serial paracenteses). It is a separate clinic from an emergency department (ED)‐based walk‐in clinic. It is also available 5 days per week; patients are seen by resident housestaff unfamiliar with the patient, and the clinic is staffed with an ambulatory attending physician. Patients are commonly seen multiple times in the same clinic, though usually with different providers.
Postdischarge Clinic
The hospitalist‐run PDC is scheduled 2 afternoons per week. Patients are always seen by housestaff and medical students from the team that cared for them as an inpatient, then staffed with a rotating hospitalist attending who may have been the supervising inpatient attending during the patient's inpatient stay. Thus, continuity is preserved with the housestaff team in all cases, although attending continuity is variable. This is added to the daily responsibility of the resident and hospitalist physicians who are providing care on the inpatient service at the time of the clinic. Capabilities of the clinic are similar to UC and PCP clinics. Patients are usually seen once postdischarge with referral to the PCP for further follow‐up; however, patients can be seen multiple times by the same provider team.
If a patient followed up with multiple clinics, the first clinic visited determined the group to which that patient was allocated for the purpose of analysis. If a patient was scheduled for clinic follow‐up but did not attend within 30 days of discharge, he or she was excluded. We did not collect data on visits outside of these 3 clinics, as pilot data demonstrated they accounted for nearly all (>90%) of posthospitalization follow‐up visits. During the study period, there were no guidelines for discharging physicians about which clinic to have the patient follow up in. The UC and PDC were known to have better early access to follow‐up appointments and thus tended to see patients requiring early follow‐up in the judgment of the discharging clinician.
Statistical Analysis
The VA's Computing and Informatics Infrastructure (VINCI) was used to collect predischarge patient data for descriptive and analytic purposes. Pertinent potential confounders included patient age, sex, marital status, comorbidities, number of prescribed medications on discharge, previous hospital admissions in the last year, ICU admission (as a dichotomous variable), ICU length of stay (LOS), and hospital LOS. Postdischarge variables included time to first follow‐up appointment and hospital LOS if readmitted.
The primary outcome was a composite of ED visits, hospital readmissions, and mortality in the 30 days following hospital discharge. These outcomes were captured in the VA system; we did not measure outside utilization. A power analysis indicated that the sample has >90% power to detect small differences (4%) in the composite outcome between types of outpatient care. We also evaluated the effect of different types of follow‐up on the 3 individual components of the primary outcome. To compare baseline categorical variables across 3 groups, 2 trend tests were used; analysis of variance (ANOVA) or Kruskal‐Wallis test was used for continuous variables in univariate analysis.
We then used propensity scoring to adjust for baseline differences between groups in an attempt to adjust for referral bias, using multivariate logistic regression to calculate a propensity score for each patient in 2‐way comparisons, and a single score for every patient in a multinomial comparison.[23] Our final propensity score incorporated age, number of hospital admissions in the past year, and Elixhauser comorbidity score,[24] with excellent overlap in propensity scores between groups. Although hospital LOS was different between groups, inclusion in the propensity score did not reduce this significant difference, and its inclusion in the propensity model decreased model fit. Limitations of the accessible data prevented high‐dimensional propensity scoring and limited the outcome of the propensity score to attendance at the clinic assigned, rather than referral to the clinic assigned. The propensity score, hospital LOS, time to the first outpatient visit, and group assignment (PDC, PCP, UC) were entered into a multivariate logistic regression model.
To find a subgroup who may benefit most from follow‐up in the PDC, we a priori identified patients with one of the 5 discharge diagnosis‐related groups (DRGs) most commonly associated with subsequent readmission[9] and examined outcomes between the 3 different kinds of follow‐up, restricted to patients discharged with one of these diagnoses. All analyses were conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
9952 patients who met criteria were discharged during this time period; however, 48.9% did not follow up with one of these clinics within 30 days, leaving 5085 patients in our analysis. Of these, 538 followed up in PDC (10.6%), 1848 followed up with their PCP (36.3%), and 2699 followed up in UC (53.1%). Table 1 presents predischarge characteristics of these patients. Patients seen in PDC were older and had a more significant comorbidity burden.
| PDC, N=538 | UC, N=2699 | PCP, N=1848 | P Value | P Value After Propensity Adjustment | |
|---|---|---|---|---|---|
| |||||
| Age, years (SD) | 67.8 (12.6) | 67.1 (13.0) | 64.8 (13.0) | <0.01 | 0.86 |
| Male sex, % | 95.0 | 95.4 | 94.4 | 0.33 | |
| Marital status, % | |||||
| Divorced | 40.2 | 36.2 | 35.0 | 0.09 | |
| Married | 35.9 | 37.3 | 39.8 | 0.13 | |
| Never married | 12.3 | 13.7 | 14.3 | 0.48 | |
| LOS, days (SD) | 3.8 (3.6) | 5.0 (11.7) | 6.2 (10.8) | 0.04 | |
| Elixhauser score (SD) | 0.80 (1.1) | 0.69 (1.0) | 0.75 (1.0) | 0.02 | 0.06 |
| Admitted to ICU, % | 19.0 | 19.9 | 23.0 | 0.12 | |
| ICU LOS, days (SD) | 2.8 (4.4) | 2.8 (3.4) | 2.3 (1.5) | 0.15 | |
| Discharge medications, mean (SD) | 10.0 (6.7) | 10.4 (7.4) | 10.4 (8.2) | 0.37 | |
| Admissions per patient in prior year, mean (SD) | 0.18 (0.5) | 0.21 (0.6) | 0.23 (0.6) | 0.08 | 0.78 |
Patients seen in PDC had a mean 2.4‐day shorter LOS than those seen by their PCPs (PDC: 3.8 days, UC: 5.0 days, PCP: 6.2 days; P=0.04 for comparison). Neither the percentage of patients admitted to the ICU during their index hospitalization nor the ICU LOS was different between groups. Patients were seen earlier postdischarge in PDC than in other types of follow‐up (PDC: 5.0 days, UC: 9.4 days, PCP: 13.7 days; P<0.01 for comparison). In univariate analysis, there was no difference between groups in the composite 30‐day outcome (Table 2). Analysis of the individual components of the primary outcome revealed significant differences in readmission rates, with PDC having the highest rate.
| PDC | UC | PCP | P Value | P Value After Propensity Adjustment | |
|---|---|---|---|---|---|
| |||||
| Composite outcome, % | 19.9 | 18.3 | 17.5 | 0.42 | 0.30 |
| Hospital readmission | 13.0 | 11.1 | 9.4 | 0.03 | 0.03 |
| ED visit | 10.2 | 9.9 | 10.5 | 0.78 | 0.93 |
| Mortality | 1.1 | 0.7 | 0.7 | 0.58 | 0.65 |
| LOS if readmitted, days (SD) | 6.9 (18.1) | 4.9 (7.8) | 4.8 (6.5) | 0.28 | 0.23 |
| Time to first visit after discharge, days (SD) | 5.0 (3.0) | 9.4 (6.1) | 13.8 (8.5) | <0.01 | <0.01 |
Univariate analyses conducted on predischarge characteristics after multinomial propensity scoring revealed significant differences between groups no longer existed for the variables that were included in the propensity score (age, Elixhauser score, and inpatient stays prior to visit; Table 1).
In multivariate analysis comparing PDC to PCP follow‐up, there was no difference in the composite outcome after controlling for propensity score and time to outpatient visit (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.81‐1.40). Similar results were obtained in comparing PDC with UC (OR: 1.05, 95% CI: 0.82‐1.34) and in multinomial logistic regression comparing PDC with other types of follow‐up (PDC vs PCP: OR: 1.01, 95% CI: 0.78‐1.31; PDC vs UC: OR: 0.99, 95% CI: 0.78‐1.26).
Restricting the multivariate analysis to those patients discharged with one of the 5 discharge DRGs most associated with readmission did not alter our findings regarding the primary outcome. We also found no change in the composite outcome or any subcomponent of the composite outcome when restricting the analysis to 7‐day outcomes or when excluding scheduled readmissions (which represented <5% of all readmission).
DISCUSSION
A hospitalist‐run postdischarge clinic did not reduce a composite of 30‐day postdischarge adverse outcomes in our study when compared with primary‐care or urgent‐care follow‐up. In fact, patients who followed up in PDC had a small increase in 30‐day readmissions. However, they also were sicker at baseline, considered higher risk by the discharging physician, were able to be seen significantly earlier, and had an associated 2.4‐day shorter hospital LOS than patients seen by their PCPs.
Our findings do not confirm those of prior research in this area, which indicated outpatient follow‐up by the same physician who was the treating inpatient physician was linked to lower mortality rates, hospital readmissions, and ED utilization.[19, 20, 21] In fact, in our study, there was a significant (albeit small) increase in 30‐day readmissions in patients seen in PDC. There are significant challenges to the generalizability and validity of these prior studies. In one study, inpatient care was provided by outpatient primary‐care doctors in Canada,[19] a payer and care model rare in the United States.[25] In a second, usual care was not specified, and it is likely the reduction in ED visits resulted from provision of follow‐up care of any kind compared with those who did not follow up after discharge.[20] In a third, the PDC was part of a larger bundle of postdischarge interventions, and it only reduced ED visits when compared with patients who did not have follow‐up; rates of ED visits were similar in a comparison with PCP follow‐up.[21]
There are several possible explanations for the lack of improvement in 30‐day adverse outcomes with a hospitalist‐run PDC. First, although early access to early postdischarge care was improved and evidence suggests this is important in reducing readmissions,[11, 12] in populations similar to that studied, more postdischarge care has also been linked to increased readmissions.[22] This may be due to more frequent re‐evaluation of fragile, chronically ill patients, presenting more options for readmission. Second, the intervention currently only addresses some components of the Ideal Transition of Care[1] (Figure 1) and may benefit from an enhanced visit structure using a multidisciplinary approach. Third, the intervention took place in the context of a robust primary‐care system with a universal electronic medical record; the effects of improved access and continuity may be magnified in a system without these advantages. Fourth, there was a low readmission rate overall, and it is unclear how many of these readmissions were preventable. Finally, it may be that although the initial postdischarge care was adequate, readmissions occurred after the first visit, suggesting subsequent care during the 30 days postdischarge could have been improved.
The most likely explanation for the substantially decreased LOS associated with follow‐up in PDC is that inpatient physicians who knew they could see their own patients early in the postdischarge process were more tolerant of uncertainty surrounding the patients' clinical course.
For example, a frequent clinical conundrum for hospitalists is when to discharge patients improving on diuretic therapy for a heart failure exacerbation or antibiotics for cellulitis. Provided a PDC, these hospitalists may choose to discharge a patient still actively being treated, because they may feel they have access to early follow‐up to change course if needed as well as the ability to see the patient themselves, allowing precise evaluation of the change in their condition. Without this clinic, the hospitalist may wonder when postdischarge follow‐up will occur. They may be more hesitant to discharge a patient who has not fully completed treatment for fear he or she will still appear decompensated to the postdischarge provider (though greatly improved from admission), or will not have timely‐enough follow‐up to change treatment if the condition worsens.
Our finding that the LOS was still shorter when comparing PDC with UC suggests continuity may be a significant component of this effect. It seems unlikely that patients following up in PDC had less complex hospitalizations given similar ICU exposure and LOS, as well as older age and larger baseline comorbidity burden.
The LOS seen in patients who followed up in PDC was lower than Medicare rates[26] but similar to reported rates at other VA acute‐care hospitals.[27] It is consistent with prior findings that hospitalist care reduces LOS,[26] though the magnitude in our study was much larger than that in prior reports. Prior studies have suggested this decreased LOS is linked to increased adverse postdischarge outcomes, such as ED visits and readmissions, as well as increased costs and decreased discharges to home.[28] The PDC was not associated with increased postdischarge adverse events measured, though a formal cost analysis and analysis of other postdischarge outcomes, such as placement in a skilled nursing or rehabilitation facility after return home, could be assessed in future work.
The findings of our study should be interpreted in the context of the study design. Our study was retrospective, observational, and single‐center. There may have been additional baseline differences between groups predisposing to bias we did not capture in the propensity score. For example, we could not measure rates of attendance at the different clinics and cannot rule out that outcomes associated with PDC were also associated with increased attendance rates. However, none of the clinics had mechanisms in place to improve follow‐up rates; patients referred to PDC were those considered highest risk for readmission and were sicker at baseline, making it very unlikely that they were predisposed to attend clinic more frequently and/or to have better outcomes; and even if PDC improved follow‐up rates, this would be a significant contribution given the limitations of primary‐care access. Our propensity score could not perfectly mimic randomization to a treatment assignment, but rather to treatment received, because of this limitation.
We did not ascertain ED visits or readmissions outside the VA system; it is possible these differentially affected one group more than another, though this seems unlikely. Our patient population was representative of veteran populations elsewhere who are at high risk of adverse postdischarge outcomes, but our findings may not be generalizable to younger, more ethnically diverse populations or to women.
CONCLUSIONS
Provision of postdischarge care by hospitalists may reduce LOS without increasing postdischarge adverse events. Further work is required to evaluate the role of hospitalist‐run PDCs in healthcare systems with more limited postdischarge access to care, to formally evaluate the costs associated with extending hospitalists to the outpatient setting, and to prospectively evaluate the role of a PDC compared with other kinds of hospital follow‐up.
Acknowledgments
The authors thank Melver Anderson, MD, for editorial assistance with the manuscript.
Disclosures: Dr. Burke had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Burke was supported by grant funding from the Colorado Research Enhancement Award Program to Improve Care Coordination for Veterans. Initial results of this study were presented at the Society of General Internal Medicine National Meeting in Denver, Colorado, April 24, 2013.
- , , , . Moving beyond readmission penalties: creating an ideal process to improve transitional care. J Hosp Med. 2013;8(2):102–109.
- , , , , , . Continuity of outpatient and inpatient care by primary care physicians for hospitalized older adults. JAMA. 2009;301(16):1671–1680.
- , , , , . Trends in inpatient continuity of care for a cohort of Medicare patients 1996–2006. J Hosp Med. 2011;6(8):438–444.
- , , , , , . Deficits in communication and information transfer between hospital‐based and primary care physicians: implications for patient safety and continuity of care. JAMA. 2007;297(8):831–841.
- , , , . Posthospital care transitions: patterns, complications, and risk identification. Health Serv Res. 2004;39(5):1449–1465.
- , , , , . Patient experiences of transitioning from hospital to home: an ethnographic quality improvement project. J Hosp Med. 2012;7(5):382–387.
- , , , et al. Understanding and execution of discharge instructions. Am J Med Qual. 2013;28(5):383–391.
- , , , , . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161–167.
- , , . Rehospitalizations among patients in the Medicare fee‐for‐service program. N Engl J Med. 2009;360(14):1418–1428.
- . Post‐hospital syndrome—an acquired, transient condition of generalized risk. N Engl J Med. 2013;368(2):100–102.
- , , , et al. Relationship between early physician follow‐up and 30‐day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716–1722.
- , , . Post‐hospitalization transitions: examining the effects of timing of primary care provider follow‐up. J Hosp Med. 2010;5(7):392–397.
- , , . Will generalist physician supply meet demands of an increasing and aging population? Health Aff (Millwood). 2008;27(3):w232–w241.
- Association of American Medical Colleges. The Impact of Health Care Reform on the Future Supply and Demand for Physicians: Updated Projections Through 2025. Available at: http://www.aamc.org/download/158076/data/updated_projections_through_2025.pdf. Published June 2010. Accessed May 1, 2012.
- , , , . Effect of discharge summary availability during post‐discharge visits on hospital readmission. J Gen Intern Med. 2002;17(3):186–192.
- , , , et al. Comprehensive quality of discharge summaries at an academic medical center. J Hosp Med. 2013;8(8):436–443.
- , , , et al. Association of communication between hospital‐based physicians and primary care providers with patient outcomes. J Gen Intern Med. 2009;24(3):381–386.
- . Is a post‐discharge clinic in your hospital's future? Available at: http://www.the‐hospitalist.org/details/article/1409011/Is_a_Post‐Discharge_Clinic_in_Your_Hospitals_Future.html. Published December 2011. Accessed May 1, 2013.
- , , , . Continuity of care and patient outcomes after hospital discharge. J Gen Intern Med. 2004;19(6):624–631.
- , , , . Effects of a postdischarge clinic on housestaff satisfaction and utilization of hospital services. J Gen Intern Med. 1996;11(3):179–181.
- , , , , , . Integrated postdischarge transitional care in a hospitalist system to improve discharge outcome: an experimental study. BMC Med. 2011;9:96.
- , , . Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334(22):1441–1447.
- , . An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32(14):1704–1708.
- , , . Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care. 2004;42(4):355–360.
- , , , . Growth in the care of older patients by hospitalists in the United States. N Engl J Med. 2009;360(11):1102–1112.
- , . Association of hospitalist care with medical utilization after discharge: evidence of cost shift from a cohort study. Ann Intern Med. 2011;155(3):152–159.
- , , , et al. Associations between reduced hospital length of stay and 30‐day readmission rate and mortality: 14‐year experience in 129 Veterans Affairs hospitals. Ann Intern Med. 2012;157(12):837–845.
- , , , . Variation in length of stay and outcomes among hospitalized patients attributable to hospitals and hospitalists. J Gen Intern Med. 2013;28(3):370–376.
Currently, healthcare systems rarely provide ideal transitions of care for discharged patients,[1] resulting in fragmented care,[2, 3, 4, 5] significant patient uncertainty about how to manage at home,[6, 7] and frequent adverse events.[8, 9] These factors are so commonly experienced by discharged patients that they are recognizable as a postdischarge syndrome.[10]
One element important for reducing the postdischarge risk of adverse events is provision of adequate follow‐up.[11, 12] However, supplying this care is challenging in the modern era, and it will become progressively more difficult to achieve. In 2004, 50% of readmitted Medicare fee‐for‐service patients had no postdischarge visit within 30 days of their discharge,[9] likely due in part to difficulty arranging such care. Changes in insurance coverage and demographics are expected to result in more than 100 million newly insured patients by 2019, yet the primary‐care workforce is projected to begin shrinking by 2016.[13, 14] In the increasingly uncommon situation that a primary‐care clinician is available promptly after discharge, information transfer is often inadequate[4, 15, 16, 17] and can be exacerbated by the growing discontinuity between inpatient and outpatient care.[2, 3, 4] Efforts to increase the supply of primary‐care clinicians and thereby improve early access to postdischarge care are important for the future, but hospitals, particularly those penalized for high risk‐adjusted readmission rates, are seeking novel solutions now.
One increasingly common innovation is to extend the role of inpatient providers (usually hospitalists) into the postdischarge period.[18] Preliminary evidence suggests improved continuity[19] and access[20] achieved by providing this care may decrease postdischarge adverse events,[19, 20, 21] though evidence is conflicting.[22]
As a closed, multilevel healthcare system, the Denver VA Medical Center is uniquely positioned to evaluate the influence of alternative postdischarge‐care strategies on subsequent adverse events. Discharged patients are seen in a well‐established hospitalist‐run postdischarge clinic (PDC), a robust urgent‐care system (UC), or by a large primary‐care provider (PCP) practice. The purpose of this study was to evaluate whether patients seen in a hospitalist‐run PDC have reduced adverse outcomes in the 30 days following hospital discharge compared with follow‐up with the patient's PCP or in an UC clinic.
METHODS
Patients
This was a retrospective cohort study of consecutive adult patients discharged from the general medical services of the Denver VA Medical Center after a nonelective admission between January 2005 and August 2012. This time range was chosen because all 3 clinics were fully operational during this period. The Denver VA Medical Center is an academically‐affiliated 128‐bed hospital that provides a full range of tertiary services. All medical patients, including intensive care unit (ICU) patients, are cared for on general medical teams by University of Colorado housestaff with hospitalists or subspecialty attendings. Patients who lived in the Denver metropolitan area, were discharged home, and who followed up with a PCP, UC clinic, or PDC within 30 days of discharge were included. Patients discharged to subacute facilities, hospice, or this tends to be capitalized as a special program at our VA were excluded. For patients with multiple admissions, only the first was included.
Clinics
Primary Care
Primary‐care clinics in the VA system are organized into Patient‐Aligned Care Teams (PACTs) and are available for appointments 5 days per week. Patients discharged from the medical service who have PCPs are called within 48 hours of discharge by PACT nurses to evaluate their postdischarge state. Primary‐care physicians could be resident housestaff or ambulatory attending physicians. Seventy‐two percent of patients seen at the Denver VA have an assigned PCP.
Urgent Care
The Office‐based Medical Team provides UC and short‐term regular appointments for recently discharged medical patients or patients who require frequent follow‐up (such as those that require serial paracenteses). It is a separate clinic from an emergency department (ED)‐based walk‐in clinic. It is also available 5 days per week; patients are seen by resident housestaff unfamiliar with the patient, and the clinic is staffed with an ambulatory attending physician. Patients are commonly seen multiple times in the same clinic, though usually with different providers.
Postdischarge Clinic
The hospitalist‐run PDC is scheduled 2 afternoons per week. Patients are always seen by housestaff and medical students from the team that cared for them as an inpatient, then staffed with a rotating hospitalist attending who may have been the supervising inpatient attending during the patient's inpatient stay. Thus, continuity is preserved with the housestaff team in all cases, although attending continuity is variable. This is added to the daily responsibility of the resident and hospitalist physicians who are providing care on the inpatient service at the time of the clinic. Capabilities of the clinic are similar to UC and PCP clinics. Patients are usually seen once postdischarge with referral to the PCP for further follow‐up; however, patients can be seen multiple times by the same provider team.
If a patient followed up with multiple clinics, the first clinic visited determined the group to which that patient was allocated for the purpose of analysis. If a patient was scheduled for clinic follow‐up but did not attend within 30 days of discharge, he or she was excluded. We did not collect data on visits outside of these 3 clinics, as pilot data demonstrated they accounted for nearly all (>90%) of posthospitalization follow‐up visits. During the study period, there were no guidelines for discharging physicians about which clinic to have the patient follow up in. The UC and PDC were known to have better early access to follow‐up appointments and thus tended to see patients requiring early follow‐up in the judgment of the discharging clinician.
Statistical Analysis
The VA's Computing and Informatics Infrastructure (VINCI) was used to collect predischarge patient data for descriptive and analytic purposes. Pertinent potential confounders included patient age, sex, marital status, comorbidities, number of prescribed medications on discharge, previous hospital admissions in the last year, ICU admission (as a dichotomous variable), ICU length of stay (LOS), and hospital LOS. Postdischarge variables included time to first follow‐up appointment and hospital LOS if readmitted.
The primary outcome was a composite of ED visits, hospital readmissions, and mortality in the 30 days following hospital discharge. These outcomes were captured in the VA system; we did not measure outside utilization. A power analysis indicated that the sample has >90% power to detect small differences (4%) in the composite outcome between types of outpatient care. We also evaluated the effect of different types of follow‐up on the 3 individual components of the primary outcome. To compare baseline categorical variables across 3 groups, 2 trend tests were used; analysis of variance (ANOVA) or Kruskal‐Wallis test was used for continuous variables in univariate analysis.
We then used propensity scoring to adjust for baseline differences between groups in an attempt to adjust for referral bias, using multivariate logistic regression to calculate a propensity score for each patient in 2‐way comparisons, and a single score for every patient in a multinomial comparison.[23] Our final propensity score incorporated age, number of hospital admissions in the past year, and Elixhauser comorbidity score,[24] with excellent overlap in propensity scores between groups. Although hospital LOS was different between groups, inclusion in the propensity score did not reduce this significant difference, and its inclusion in the propensity model decreased model fit. Limitations of the accessible data prevented high‐dimensional propensity scoring and limited the outcome of the propensity score to attendance at the clinic assigned, rather than referral to the clinic assigned. The propensity score, hospital LOS, time to the first outpatient visit, and group assignment (PDC, PCP, UC) were entered into a multivariate logistic regression model.
To find a subgroup who may benefit most from follow‐up in the PDC, we a priori identified patients with one of the 5 discharge diagnosis‐related groups (DRGs) most commonly associated with subsequent readmission[9] and examined outcomes between the 3 different kinds of follow‐up, restricted to patients discharged with one of these diagnoses. All analyses were conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
9952 patients who met criteria were discharged during this time period; however, 48.9% did not follow up with one of these clinics within 30 days, leaving 5085 patients in our analysis. Of these, 538 followed up in PDC (10.6%), 1848 followed up with their PCP (36.3%), and 2699 followed up in UC (53.1%). Table 1 presents predischarge characteristics of these patients. Patients seen in PDC were older and had a more significant comorbidity burden.
| PDC, N=538 | UC, N=2699 | PCP, N=1848 | P Value | P Value After Propensity Adjustment | |
|---|---|---|---|---|---|
| |||||
| Age, years (SD) | 67.8 (12.6) | 67.1 (13.0) | 64.8 (13.0) | <0.01 | 0.86 |
| Male sex, % | 95.0 | 95.4 | 94.4 | 0.33 | |
| Marital status, % | |||||
| Divorced | 40.2 | 36.2 | 35.0 | 0.09 | |
| Married | 35.9 | 37.3 | 39.8 | 0.13 | |
| Never married | 12.3 | 13.7 | 14.3 | 0.48 | |
| LOS, days (SD) | 3.8 (3.6) | 5.0 (11.7) | 6.2 (10.8) | 0.04 | |
| Elixhauser score (SD) | 0.80 (1.1) | 0.69 (1.0) | 0.75 (1.0) | 0.02 | 0.06 |
| Admitted to ICU, % | 19.0 | 19.9 | 23.0 | 0.12 | |
| ICU LOS, days (SD) | 2.8 (4.4) | 2.8 (3.4) | 2.3 (1.5) | 0.15 | |
| Discharge medications, mean (SD) | 10.0 (6.7) | 10.4 (7.4) | 10.4 (8.2) | 0.37 | |
| Admissions per patient in prior year, mean (SD) | 0.18 (0.5) | 0.21 (0.6) | 0.23 (0.6) | 0.08 | 0.78 |
Patients seen in PDC had a mean 2.4‐day shorter LOS than those seen by their PCPs (PDC: 3.8 days, UC: 5.0 days, PCP: 6.2 days; P=0.04 for comparison). Neither the percentage of patients admitted to the ICU during their index hospitalization nor the ICU LOS was different between groups. Patients were seen earlier postdischarge in PDC than in other types of follow‐up (PDC: 5.0 days, UC: 9.4 days, PCP: 13.7 days; P<0.01 for comparison). In univariate analysis, there was no difference between groups in the composite 30‐day outcome (Table 2). Analysis of the individual components of the primary outcome revealed significant differences in readmission rates, with PDC having the highest rate.
| PDC | UC | PCP | P Value | P Value After Propensity Adjustment | |
|---|---|---|---|---|---|
| |||||
| Composite outcome, % | 19.9 | 18.3 | 17.5 | 0.42 | 0.30 |
| Hospital readmission | 13.0 | 11.1 | 9.4 | 0.03 | 0.03 |
| ED visit | 10.2 | 9.9 | 10.5 | 0.78 | 0.93 |
| Mortality | 1.1 | 0.7 | 0.7 | 0.58 | 0.65 |
| LOS if readmitted, days (SD) | 6.9 (18.1) | 4.9 (7.8) | 4.8 (6.5) | 0.28 | 0.23 |
| Time to first visit after discharge, days (SD) | 5.0 (3.0) | 9.4 (6.1) | 13.8 (8.5) | <0.01 | <0.01 |
Univariate analyses conducted on predischarge characteristics after multinomial propensity scoring revealed significant differences between groups no longer existed for the variables that were included in the propensity score (age, Elixhauser score, and inpatient stays prior to visit; Table 1).
In multivariate analysis comparing PDC to PCP follow‐up, there was no difference in the composite outcome after controlling for propensity score and time to outpatient visit (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.81‐1.40). Similar results were obtained in comparing PDC with UC (OR: 1.05, 95% CI: 0.82‐1.34) and in multinomial logistic regression comparing PDC with other types of follow‐up (PDC vs PCP: OR: 1.01, 95% CI: 0.78‐1.31; PDC vs UC: OR: 0.99, 95% CI: 0.78‐1.26).
Restricting the multivariate analysis to those patients discharged with one of the 5 discharge DRGs most associated with readmission did not alter our findings regarding the primary outcome. We also found no change in the composite outcome or any subcomponent of the composite outcome when restricting the analysis to 7‐day outcomes or when excluding scheduled readmissions (which represented <5% of all readmission).
DISCUSSION
A hospitalist‐run postdischarge clinic did not reduce a composite of 30‐day postdischarge adverse outcomes in our study when compared with primary‐care or urgent‐care follow‐up. In fact, patients who followed up in PDC had a small increase in 30‐day readmissions. However, they also were sicker at baseline, considered higher risk by the discharging physician, were able to be seen significantly earlier, and had an associated 2.4‐day shorter hospital LOS than patients seen by their PCPs.
Our findings do not confirm those of prior research in this area, which indicated outpatient follow‐up by the same physician who was the treating inpatient physician was linked to lower mortality rates, hospital readmissions, and ED utilization.[19, 20, 21] In fact, in our study, there was a significant (albeit small) increase in 30‐day readmissions in patients seen in PDC. There are significant challenges to the generalizability and validity of these prior studies. In one study, inpatient care was provided by outpatient primary‐care doctors in Canada,[19] a payer and care model rare in the United States.[25] In a second, usual care was not specified, and it is likely the reduction in ED visits resulted from provision of follow‐up care of any kind compared with those who did not follow up after discharge.[20] In a third, the PDC was part of a larger bundle of postdischarge interventions, and it only reduced ED visits when compared with patients who did not have follow‐up; rates of ED visits were similar in a comparison with PCP follow‐up.[21]
There are several possible explanations for the lack of improvement in 30‐day adverse outcomes with a hospitalist‐run PDC. First, although early access to early postdischarge care was improved and evidence suggests this is important in reducing readmissions,[11, 12] in populations similar to that studied, more postdischarge care has also been linked to increased readmissions.[22] This may be due to more frequent re‐evaluation of fragile, chronically ill patients, presenting more options for readmission. Second, the intervention currently only addresses some components of the Ideal Transition of Care[1] (Figure 1) and may benefit from an enhanced visit structure using a multidisciplinary approach. Third, the intervention took place in the context of a robust primary‐care system with a universal electronic medical record; the effects of improved access and continuity may be magnified in a system without these advantages. Fourth, there was a low readmission rate overall, and it is unclear how many of these readmissions were preventable. Finally, it may be that although the initial postdischarge care was adequate, readmissions occurred after the first visit, suggesting subsequent care during the 30 days postdischarge could have been improved.
The most likely explanation for the substantially decreased LOS associated with follow‐up in PDC is that inpatient physicians who knew they could see their own patients early in the postdischarge process were more tolerant of uncertainty surrounding the patients' clinical course.
For example, a frequent clinical conundrum for hospitalists is when to discharge patients improving on diuretic therapy for a heart failure exacerbation or antibiotics for cellulitis. Provided a PDC, these hospitalists may choose to discharge a patient still actively being treated, because they may feel they have access to early follow‐up to change course if needed as well as the ability to see the patient themselves, allowing precise evaluation of the change in their condition. Without this clinic, the hospitalist may wonder when postdischarge follow‐up will occur. They may be more hesitant to discharge a patient who has not fully completed treatment for fear he or she will still appear decompensated to the postdischarge provider (though greatly improved from admission), or will not have timely‐enough follow‐up to change treatment if the condition worsens.
Our finding that the LOS was still shorter when comparing PDC with UC suggests continuity may be a significant component of this effect. It seems unlikely that patients following up in PDC had less complex hospitalizations given similar ICU exposure and LOS, as well as older age and larger baseline comorbidity burden.
The LOS seen in patients who followed up in PDC was lower than Medicare rates[26] but similar to reported rates at other VA acute‐care hospitals.[27] It is consistent with prior findings that hospitalist care reduces LOS,[26] though the magnitude in our study was much larger than that in prior reports. Prior studies have suggested this decreased LOS is linked to increased adverse postdischarge outcomes, such as ED visits and readmissions, as well as increased costs and decreased discharges to home.[28] The PDC was not associated with increased postdischarge adverse events measured, though a formal cost analysis and analysis of other postdischarge outcomes, such as placement in a skilled nursing or rehabilitation facility after return home, could be assessed in future work.
The findings of our study should be interpreted in the context of the study design. Our study was retrospective, observational, and single‐center. There may have been additional baseline differences between groups predisposing to bias we did not capture in the propensity score. For example, we could not measure rates of attendance at the different clinics and cannot rule out that outcomes associated with PDC were also associated with increased attendance rates. However, none of the clinics had mechanisms in place to improve follow‐up rates; patients referred to PDC were those considered highest risk for readmission and were sicker at baseline, making it very unlikely that they were predisposed to attend clinic more frequently and/or to have better outcomes; and even if PDC improved follow‐up rates, this would be a significant contribution given the limitations of primary‐care access. Our propensity score could not perfectly mimic randomization to a treatment assignment, but rather to treatment received, because of this limitation.
We did not ascertain ED visits or readmissions outside the VA system; it is possible these differentially affected one group more than another, though this seems unlikely. Our patient population was representative of veteran populations elsewhere who are at high risk of adverse postdischarge outcomes, but our findings may not be generalizable to younger, more ethnically diverse populations or to women.
CONCLUSIONS
Provision of postdischarge care by hospitalists may reduce LOS without increasing postdischarge adverse events. Further work is required to evaluate the role of hospitalist‐run PDCs in healthcare systems with more limited postdischarge access to care, to formally evaluate the costs associated with extending hospitalists to the outpatient setting, and to prospectively evaluate the role of a PDC compared with other kinds of hospital follow‐up.
Acknowledgments
The authors thank Melver Anderson, MD, for editorial assistance with the manuscript.
Disclosures: Dr. Burke had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Burke was supported by grant funding from the Colorado Research Enhancement Award Program to Improve Care Coordination for Veterans. Initial results of this study were presented at the Society of General Internal Medicine National Meeting in Denver, Colorado, April 24, 2013.
Currently, healthcare systems rarely provide ideal transitions of care for discharged patients,[1] resulting in fragmented care,[2, 3, 4, 5] significant patient uncertainty about how to manage at home,[6, 7] and frequent adverse events.[8, 9] These factors are so commonly experienced by discharged patients that they are recognizable as a postdischarge syndrome.[10]
One element important for reducing the postdischarge risk of adverse events is provision of adequate follow‐up.[11, 12] However, supplying this care is challenging in the modern era, and it will become progressively more difficult to achieve. In 2004, 50% of readmitted Medicare fee‐for‐service patients had no postdischarge visit within 30 days of their discharge,[9] likely due in part to difficulty arranging such care. Changes in insurance coverage and demographics are expected to result in more than 100 million newly insured patients by 2019, yet the primary‐care workforce is projected to begin shrinking by 2016.[13, 14] In the increasingly uncommon situation that a primary‐care clinician is available promptly after discharge, information transfer is often inadequate[4, 15, 16, 17] and can be exacerbated by the growing discontinuity between inpatient and outpatient care.[2, 3, 4] Efforts to increase the supply of primary‐care clinicians and thereby improve early access to postdischarge care are important for the future, but hospitals, particularly those penalized for high risk‐adjusted readmission rates, are seeking novel solutions now.
One increasingly common innovation is to extend the role of inpatient providers (usually hospitalists) into the postdischarge period.[18] Preliminary evidence suggests improved continuity[19] and access[20] achieved by providing this care may decrease postdischarge adverse events,[19, 20, 21] though evidence is conflicting.[22]
As a closed, multilevel healthcare system, the Denver VA Medical Center is uniquely positioned to evaluate the influence of alternative postdischarge‐care strategies on subsequent adverse events. Discharged patients are seen in a well‐established hospitalist‐run postdischarge clinic (PDC), a robust urgent‐care system (UC), or by a large primary‐care provider (PCP) practice. The purpose of this study was to evaluate whether patients seen in a hospitalist‐run PDC have reduced adverse outcomes in the 30 days following hospital discharge compared with follow‐up with the patient's PCP or in an UC clinic.
METHODS
Patients
This was a retrospective cohort study of consecutive adult patients discharged from the general medical services of the Denver VA Medical Center after a nonelective admission between January 2005 and August 2012. This time range was chosen because all 3 clinics were fully operational during this period. The Denver VA Medical Center is an academically‐affiliated 128‐bed hospital that provides a full range of tertiary services. All medical patients, including intensive care unit (ICU) patients, are cared for on general medical teams by University of Colorado housestaff with hospitalists or subspecialty attendings. Patients who lived in the Denver metropolitan area, were discharged home, and who followed up with a PCP, UC clinic, or PDC within 30 days of discharge were included. Patients discharged to subacute facilities, hospice, or this tends to be capitalized as a special program at our VA were excluded. For patients with multiple admissions, only the first was included.
Clinics
Primary Care
Primary‐care clinics in the VA system are organized into Patient‐Aligned Care Teams (PACTs) and are available for appointments 5 days per week. Patients discharged from the medical service who have PCPs are called within 48 hours of discharge by PACT nurses to evaluate their postdischarge state. Primary‐care physicians could be resident housestaff or ambulatory attending physicians. Seventy‐two percent of patients seen at the Denver VA have an assigned PCP.
Urgent Care
The Office‐based Medical Team provides UC and short‐term regular appointments for recently discharged medical patients or patients who require frequent follow‐up (such as those that require serial paracenteses). It is a separate clinic from an emergency department (ED)‐based walk‐in clinic. It is also available 5 days per week; patients are seen by resident housestaff unfamiliar with the patient, and the clinic is staffed with an ambulatory attending physician. Patients are commonly seen multiple times in the same clinic, though usually with different providers.
Postdischarge Clinic
The hospitalist‐run PDC is scheduled 2 afternoons per week. Patients are always seen by housestaff and medical students from the team that cared for them as an inpatient, then staffed with a rotating hospitalist attending who may have been the supervising inpatient attending during the patient's inpatient stay. Thus, continuity is preserved with the housestaff team in all cases, although attending continuity is variable. This is added to the daily responsibility of the resident and hospitalist physicians who are providing care on the inpatient service at the time of the clinic. Capabilities of the clinic are similar to UC and PCP clinics. Patients are usually seen once postdischarge with referral to the PCP for further follow‐up; however, patients can be seen multiple times by the same provider team.
If a patient followed up with multiple clinics, the first clinic visited determined the group to which that patient was allocated for the purpose of analysis. If a patient was scheduled for clinic follow‐up but did not attend within 30 days of discharge, he or she was excluded. We did not collect data on visits outside of these 3 clinics, as pilot data demonstrated they accounted for nearly all (>90%) of posthospitalization follow‐up visits. During the study period, there were no guidelines for discharging physicians about which clinic to have the patient follow up in. The UC and PDC were known to have better early access to follow‐up appointments and thus tended to see patients requiring early follow‐up in the judgment of the discharging clinician.
Statistical Analysis
The VA's Computing and Informatics Infrastructure (VINCI) was used to collect predischarge patient data for descriptive and analytic purposes. Pertinent potential confounders included patient age, sex, marital status, comorbidities, number of prescribed medications on discharge, previous hospital admissions in the last year, ICU admission (as a dichotomous variable), ICU length of stay (LOS), and hospital LOS. Postdischarge variables included time to first follow‐up appointment and hospital LOS if readmitted.
The primary outcome was a composite of ED visits, hospital readmissions, and mortality in the 30 days following hospital discharge. These outcomes were captured in the VA system; we did not measure outside utilization. A power analysis indicated that the sample has >90% power to detect small differences (4%) in the composite outcome between types of outpatient care. We also evaluated the effect of different types of follow‐up on the 3 individual components of the primary outcome. To compare baseline categorical variables across 3 groups, 2 trend tests were used; analysis of variance (ANOVA) or Kruskal‐Wallis test was used for continuous variables in univariate analysis.
We then used propensity scoring to adjust for baseline differences between groups in an attempt to adjust for referral bias, using multivariate logistic regression to calculate a propensity score for each patient in 2‐way comparisons, and a single score for every patient in a multinomial comparison.[23] Our final propensity score incorporated age, number of hospital admissions in the past year, and Elixhauser comorbidity score,[24] with excellent overlap in propensity scores between groups. Although hospital LOS was different between groups, inclusion in the propensity score did not reduce this significant difference, and its inclusion in the propensity model decreased model fit. Limitations of the accessible data prevented high‐dimensional propensity scoring and limited the outcome of the propensity score to attendance at the clinic assigned, rather than referral to the clinic assigned. The propensity score, hospital LOS, time to the first outpatient visit, and group assignment (PDC, PCP, UC) were entered into a multivariate logistic regression model.
To find a subgroup who may benefit most from follow‐up in the PDC, we a priori identified patients with one of the 5 discharge diagnosis‐related groups (DRGs) most commonly associated with subsequent readmission[9] and examined outcomes between the 3 different kinds of follow‐up, restricted to patients discharged with one of these diagnoses. All analyses were conducted using SAS 9.3 (SAS Institute, Inc., Cary, NC).
RESULTS
9952 patients who met criteria were discharged during this time period; however, 48.9% did not follow up with one of these clinics within 30 days, leaving 5085 patients in our analysis. Of these, 538 followed up in PDC (10.6%), 1848 followed up with their PCP (36.3%), and 2699 followed up in UC (53.1%). Table 1 presents predischarge characteristics of these patients. Patients seen in PDC were older and had a more significant comorbidity burden.
| PDC, N=538 | UC, N=2699 | PCP, N=1848 | P Value | P Value After Propensity Adjustment | |
|---|---|---|---|---|---|
| |||||
| Age, years (SD) | 67.8 (12.6) | 67.1 (13.0) | 64.8 (13.0) | <0.01 | 0.86 |
| Male sex, % | 95.0 | 95.4 | 94.4 | 0.33 | |
| Marital status, % | |||||
| Divorced | 40.2 | 36.2 | 35.0 | 0.09 | |
| Married | 35.9 | 37.3 | 39.8 | 0.13 | |
| Never married | 12.3 | 13.7 | 14.3 | 0.48 | |
| LOS, days (SD) | 3.8 (3.6) | 5.0 (11.7) | 6.2 (10.8) | 0.04 | |
| Elixhauser score (SD) | 0.80 (1.1) | 0.69 (1.0) | 0.75 (1.0) | 0.02 | 0.06 |
| Admitted to ICU, % | 19.0 | 19.9 | 23.0 | 0.12 | |
| ICU LOS, days (SD) | 2.8 (4.4) | 2.8 (3.4) | 2.3 (1.5) | 0.15 | |
| Discharge medications, mean (SD) | 10.0 (6.7) | 10.4 (7.4) | 10.4 (8.2) | 0.37 | |
| Admissions per patient in prior year, mean (SD) | 0.18 (0.5) | 0.21 (0.6) | 0.23 (0.6) | 0.08 | 0.78 |
Patients seen in PDC had a mean 2.4‐day shorter LOS than those seen by their PCPs (PDC: 3.8 days, UC: 5.0 days, PCP: 6.2 days; P=0.04 for comparison). Neither the percentage of patients admitted to the ICU during their index hospitalization nor the ICU LOS was different between groups. Patients were seen earlier postdischarge in PDC than in other types of follow‐up (PDC: 5.0 days, UC: 9.4 days, PCP: 13.7 days; P<0.01 for comparison). In univariate analysis, there was no difference between groups in the composite 30‐day outcome (Table 2). Analysis of the individual components of the primary outcome revealed significant differences in readmission rates, with PDC having the highest rate.
| PDC | UC | PCP | P Value | P Value After Propensity Adjustment | |
|---|---|---|---|---|---|
| |||||
| Composite outcome, % | 19.9 | 18.3 | 17.5 | 0.42 | 0.30 |
| Hospital readmission | 13.0 | 11.1 | 9.4 | 0.03 | 0.03 |
| ED visit | 10.2 | 9.9 | 10.5 | 0.78 | 0.93 |
| Mortality | 1.1 | 0.7 | 0.7 | 0.58 | 0.65 |
| LOS if readmitted, days (SD) | 6.9 (18.1) | 4.9 (7.8) | 4.8 (6.5) | 0.28 | 0.23 |
| Time to first visit after discharge, days (SD) | 5.0 (3.0) | 9.4 (6.1) | 13.8 (8.5) | <0.01 | <0.01 |
Univariate analyses conducted on predischarge characteristics after multinomial propensity scoring revealed significant differences between groups no longer existed for the variables that were included in the propensity score (age, Elixhauser score, and inpatient stays prior to visit; Table 1).
In multivariate analysis comparing PDC to PCP follow‐up, there was no difference in the composite outcome after controlling for propensity score and time to outpatient visit (odds ratio [OR]: 1.07, 95% confidence interval [CI]: 0.81‐1.40). Similar results were obtained in comparing PDC with UC (OR: 1.05, 95% CI: 0.82‐1.34) and in multinomial logistic regression comparing PDC with other types of follow‐up (PDC vs PCP: OR: 1.01, 95% CI: 0.78‐1.31; PDC vs UC: OR: 0.99, 95% CI: 0.78‐1.26).
Restricting the multivariate analysis to those patients discharged with one of the 5 discharge DRGs most associated with readmission did not alter our findings regarding the primary outcome. We also found no change in the composite outcome or any subcomponent of the composite outcome when restricting the analysis to 7‐day outcomes or when excluding scheduled readmissions (which represented <5% of all readmission).
DISCUSSION
A hospitalist‐run postdischarge clinic did not reduce a composite of 30‐day postdischarge adverse outcomes in our study when compared with primary‐care or urgent‐care follow‐up. In fact, patients who followed up in PDC had a small increase in 30‐day readmissions. However, they also were sicker at baseline, considered higher risk by the discharging physician, were able to be seen significantly earlier, and had an associated 2.4‐day shorter hospital LOS than patients seen by their PCPs.
Our findings do not confirm those of prior research in this area, which indicated outpatient follow‐up by the same physician who was the treating inpatient physician was linked to lower mortality rates, hospital readmissions, and ED utilization.[19, 20, 21] In fact, in our study, there was a significant (albeit small) increase in 30‐day readmissions in patients seen in PDC. There are significant challenges to the generalizability and validity of these prior studies. In one study, inpatient care was provided by outpatient primary‐care doctors in Canada,[19] a payer and care model rare in the United States.[25] In a second, usual care was not specified, and it is likely the reduction in ED visits resulted from provision of follow‐up care of any kind compared with those who did not follow up after discharge.[20] In a third, the PDC was part of a larger bundle of postdischarge interventions, and it only reduced ED visits when compared with patients who did not have follow‐up; rates of ED visits were similar in a comparison with PCP follow‐up.[21]
There are several possible explanations for the lack of improvement in 30‐day adverse outcomes with a hospitalist‐run PDC. First, although early access to early postdischarge care was improved and evidence suggests this is important in reducing readmissions,[11, 12] in populations similar to that studied, more postdischarge care has also been linked to increased readmissions.[22] This may be due to more frequent re‐evaluation of fragile, chronically ill patients, presenting more options for readmission. Second, the intervention currently only addresses some components of the Ideal Transition of Care[1] (Figure 1) and may benefit from an enhanced visit structure using a multidisciplinary approach. Third, the intervention took place in the context of a robust primary‐care system with a universal electronic medical record; the effects of improved access and continuity may be magnified in a system without these advantages. Fourth, there was a low readmission rate overall, and it is unclear how many of these readmissions were preventable. Finally, it may be that although the initial postdischarge care was adequate, readmissions occurred after the first visit, suggesting subsequent care during the 30 days postdischarge could have been improved.
The most likely explanation for the substantially decreased LOS associated with follow‐up in PDC is that inpatient physicians who knew they could see their own patients early in the postdischarge process were more tolerant of uncertainty surrounding the patients' clinical course.
For example, a frequent clinical conundrum for hospitalists is when to discharge patients improving on diuretic therapy for a heart failure exacerbation or antibiotics for cellulitis. Provided a PDC, these hospitalists may choose to discharge a patient still actively being treated, because they may feel they have access to early follow‐up to change course if needed as well as the ability to see the patient themselves, allowing precise evaluation of the change in their condition. Without this clinic, the hospitalist may wonder when postdischarge follow‐up will occur. They may be more hesitant to discharge a patient who has not fully completed treatment for fear he or she will still appear decompensated to the postdischarge provider (though greatly improved from admission), or will not have timely‐enough follow‐up to change treatment if the condition worsens.
Our finding that the LOS was still shorter when comparing PDC with UC suggests continuity may be a significant component of this effect. It seems unlikely that patients following up in PDC had less complex hospitalizations given similar ICU exposure and LOS, as well as older age and larger baseline comorbidity burden.
The LOS seen in patients who followed up in PDC was lower than Medicare rates[26] but similar to reported rates at other VA acute‐care hospitals.[27] It is consistent with prior findings that hospitalist care reduces LOS,[26] though the magnitude in our study was much larger than that in prior reports. Prior studies have suggested this decreased LOS is linked to increased adverse postdischarge outcomes, such as ED visits and readmissions, as well as increased costs and decreased discharges to home.[28] The PDC was not associated with increased postdischarge adverse events measured, though a formal cost analysis and analysis of other postdischarge outcomes, such as placement in a skilled nursing or rehabilitation facility after return home, could be assessed in future work.
The findings of our study should be interpreted in the context of the study design. Our study was retrospective, observational, and single‐center. There may have been additional baseline differences between groups predisposing to bias we did not capture in the propensity score. For example, we could not measure rates of attendance at the different clinics and cannot rule out that outcomes associated with PDC were also associated with increased attendance rates. However, none of the clinics had mechanisms in place to improve follow‐up rates; patients referred to PDC were those considered highest risk for readmission and were sicker at baseline, making it very unlikely that they were predisposed to attend clinic more frequently and/or to have better outcomes; and even if PDC improved follow‐up rates, this would be a significant contribution given the limitations of primary‐care access. Our propensity score could not perfectly mimic randomization to a treatment assignment, but rather to treatment received, because of this limitation.
We did not ascertain ED visits or readmissions outside the VA system; it is possible these differentially affected one group more than another, though this seems unlikely. Our patient population was representative of veteran populations elsewhere who are at high risk of adverse postdischarge outcomes, but our findings may not be generalizable to younger, more ethnically diverse populations or to women.
CONCLUSIONS
Provision of postdischarge care by hospitalists may reduce LOS without increasing postdischarge adverse events. Further work is required to evaluate the role of hospitalist‐run PDCs in healthcare systems with more limited postdischarge access to care, to formally evaluate the costs associated with extending hospitalists to the outpatient setting, and to prospectively evaluate the role of a PDC compared with other kinds of hospital follow‐up.
Acknowledgments
The authors thank Melver Anderson, MD, for editorial assistance with the manuscript.
Disclosures: Dr. Burke had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Dr. Burke was supported by grant funding from the Colorado Research Enhancement Award Program to Improve Care Coordination for Veterans. Initial results of this study were presented at the Society of General Internal Medicine National Meeting in Denver, Colorado, April 24, 2013.
- , , , . Moving beyond readmission penalties: creating an ideal process to improve transitional care. J Hosp Med. 2013;8(2):102–109.
- , , , , , . Continuity of outpatient and inpatient care by primary care physicians for hospitalized older adults. JAMA. 2009;301(16):1671–1680.
- , , , , . Trends in inpatient continuity of care for a cohort of Medicare patients 1996–2006. J Hosp Med. 2011;6(8):438–444.
- , , , , , . Deficits in communication and information transfer between hospital‐based and primary care physicians: implications for patient safety and continuity of care. JAMA. 2007;297(8):831–841.
- , , , . Posthospital care transitions: patterns, complications, and risk identification. Health Serv Res. 2004;39(5):1449–1465.
- , , , , . Patient experiences of transitioning from hospital to home: an ethnographic quality improvement project. J Hosp Med. 2012;7(5):382–387.
- , , , et al. Understanding and execution of discharge instructions. Am J Med Qual. 2013;28(5):383–391.
- , , , , . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161–167.
- , , . Rehospitalizations among patients in the Medicare fee‐for‐service program. N Engl J Med. 2009;360(14):1418–1428.
- . Post‐hospital syndrome—an acquired, transient condition of generalized risk. N Engl J Med. 2013;368(2):100–102.
- , , , et al. Relationship between early physician follow‐up and 30‐day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716–1722.
- , , . Post‐hospitalization transitions: examining the effects of timing of primary care provider follow‐up. J Hosp Med. 2010;5(7):392–397.
- , , . Will generalist physician supply meet demands of an increasing and aging population? Health Aff (Millwood). 2008;27(3):w232–w241.
- Association of American Medical Colleges. The Impact of Health Care Reform on the Future Supply and Demand for Physicians: Updated Projections Through 2025. Available at: http://www.aamc.org/download/158076/data/updated_projections_through_2025.pdf. Published June 2010. Accessed May 1, 2012.
- , , , . Effect of discharge summary availability during post‐discharge visits on hospital readmission. J Gen Intern Med. 2002;17(3):186–192.
- , , , et al. Comprehensive quality of discharge summaries at an academic medical center. J Hosp Med. 2013;8(8):436–443.
- , , , et al. Association of communication between hospital‐based physicians and primary care providers with patient outcomes. J Gen Intern Med. 2009;24(3):381–386.
- . Is a post‐discharge clinic in your hospital's future? Available at: http://www.the‐hospitalist.org/details/article/1409011/Is_a_Post‐Discharge_Clinic_in_Your_Hospitals_Future.html. Published December 2011. Accessed May 1, 2013.
- , , , . Continuity of care and patient outcomes after hospital discharge. J Gen Intern Med. 2004;19(6):624–631.
- , , , . Effects of a postdischarge clinic on housestaff satisfaction and utilization of hospital services. J Gen Intern Med. 1996;11(3):179–181.
- , , , , , . Integrated postdischarge transitional care in a hospitalist system to improve discharge outcome: an experimental study. BMC Med. 2011;9:96.
- , , . Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334(22):1441–1447.
- , . An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32(14):1704–1708.
- , , . Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care. 2004;42(4):355–360.
- , , , . Growth in the care of older patients by hospitalists in the United States. N Engl J Med. 2009;360(11):1102–1112.
- , . Association of hospitalist care with medical utilization after discharge: evidence of cost shift from a cohort study. Ann Intern Med. 2011;155(3):152–159.
- , , , et al. Associations between reduced hospital length of stay and 30‐day readmission rate and mortality: 14‐year experience in 129 Veterans Affairs hospitals. Ann Intern Med. 2012;157(12):837–845.
- , , , . Variation in length of stay and outcomes among hospitalized patients attributable to hospitals and hospitalists. J Gen Intern Med. 2013;28(3):370–376.
- , , , . Moving beyond readmission penalties: creating an ideal process to improve transitional care. J Hosp Med. 2013;8(2):102–109.
- , , , , , . Continuity of outpatient and inpatient care by primary care physicians for hospitalized older adults. JAMA. 2009;301(16):1671–1680.
- , , , , . Trends in inpatient continuity of care for a cohort of Medicare patients 1996–2006. J Hosp Med. 2011;6(8):438–444.
- , , , , , . Deficits in communication and information transfer between hospital‐based and primary care physicians: implications for patient safety and continuity of care. JAMA. 2007;297(8):831–841.
- , , , . Posthospital care transitions: patterns, complications, and risk identification. Health Serv Res. 2004;39(5):1449–1465.
- , , , , . Patient experiences of transitioning from hospital to home: an ethnographic quality improvement project. J Hosp Med. 2012;7(5):382–387.
- , , , et al. Understanding and execution of discharge instructions. Am J Med Qual. 2013;28(5):383–391.
- , , , , . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161–167.
- , , . Rehospitalizations among patients in the Medicare fee‐for‐service program. N Engl J Med. 2009;360(14):1418–1428.
- . Post‐hospital syndrome—an acquired, transient condition of generalized risk. N Engl J Med. 2013;368(2):100–102.
- , , , et al. Relationship between early physician follow‐up and 30‐day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010;303(17):1716–1722.
- , , . Post‐hospitalization transitions: examining the effects of timing of primary care provider follow‐up. J Hosp Med. 2010;5(7):392–397.
- , , . Will generalist physician supply meet demands of an increasing and aging population? Health Aff (Millwood). 2008;27(3):w232–w241.
- Association of American Medical Colleges. The Impact of Health Care Reform on the Future Supply and Demand for Physicians: Updated Projections Through 2025. Available at: http://www.aamc.org/download/158076/data/updated_projections_through_2025.pdf. Published June 2010. Accessed May 1, 2012.
- , , , . Effect of discharge summary availability during post‐discharge visits on hospital readmission. J Gen Intern Med. 2002;17(3):186–192.
- , , , et al. Comprehensive quality of discharge summaries at an academic medical center. J Hosp Med. 2013;8(8):436–443.
- , , , et al. Association of communication between hospital‐based physicians and primary care providers with patient outcomes. J Gen Intern Med. 2009;24(3):381–386.
- . Is a post‐discharge clinic in your hospital's future? Available at: http://www.the‐hospitalist.org/details/article/1409011/Is_a_Post‐Discharge_Clinic_in_Your_Hospitals_Future.html. Published December 2011. Accessed May 1, 2013.
- , , , . Continuity of care and patient outcomes after hospital discharge. J Gen Intern Med. 2004;19(6):624–631.
- , , , . Effects of a postdischarge clinic on housestaff satisfaction and utilization of hospital services. J Gen Intern Med. 1996;11(3):179–181.
- , , , , , . Integrated postdischarge transitional care in a hospitalist system to improve discharge outcome: an experimental study. BMC Med. 2011;9:96.
- , , . Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334(22):1441–1447.
- , . An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J. 2011;32(14):1704–1708.
- , , . Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care. 2004;42(4):355–360.
- , , , . Growth in the care of older patients by hospitalists in the United States. N Engl J Med. 2009;360(11):1102–1112.
- , . Association of hospitalist care with medical utilization after discharge: evidence of cost shift from a cohort study. Ann Intern Med. 2011;155(3):152–159.
- , , , et al. Associations between reduced hospital length of stay and 30‐day readmission rate and mortality: 14‐year experience in 129 Veterans Affairs hospitals. Ann Intern Med. 2012;157(12):837–845.
- , , , . Variation in length of stay and outcomes among hospitalized patients attributable to hospitals and hospitalists. J Gen Intern Med. 2013;28(3):370–376.
© 2013 Society of Hospital Medicine
PCP Communication at Hospital Discharge
Medication errors occur frequently when patients transition care between providers, such as the transition from hospital to home.[1] Approximately 50% of about 3 million adults per year over 65 years of age transitioning from hospital to home experience a medication discrepancy.[1] At hospital discharge, patients with complex medical problems are prescribed multiple medications with complex dosing and schedules. To add to this complexity, many patients also have cognitive impairment, variable health literacy, and limited social and financial support. Patients with medication discrepancies have significantly higher rates of rehospitalization compared to those without medication discrepancies.[2] Thus, interventions that focus on patients at greater risk of medication discrepancies may identify those at greater risk of subsequent rehospitalization and potentially reduce the rates of readmissions.[3]
There is limited evidence to date on the effectiveness of interventions to decrease post‐hospitalization medication discrepancies.[3, 4, 5, 6] Previous transitional care interventions have been expensive and difficult to sustain due to the need for multiple additional transitional care personnel (e.g., care managers, nurses, pharmacists, transitional care coaches).[7, 8, 9, 10] Moreover, these additional personnel may further fragment the care of hospitalized patients with additional handoffs.
As both hospitalists and outpatient primary care physicians (PCPs) are being expected to care for larger numbers of increasingly sicker patients, the communication handoff of patient information at discharge remains a challenge.[11] Both patients and PCPs often obtain incomplete or inaccurate information and instructions at discharge. Follow‐up appointments are often missed or delayed.[12] Many hospital‐based interventions do not directly involve the PCP or take advantage of the already established PCPpatient relationship.
We conducted a pilot study examining whether enhancing PCP communication with patients at hospital discharge would impact medication discrepancies and improve the safety of the patient as they transitioned home from the hospital.
METHODS
Recruitment of Subjects
The institutional review board of Northwestern University approved this study. Accessing the hospital electronic health record, research staff queried admission information and contacted the hospital physician to determine potential subject eligibility. Research staff recruited consecutive community‐dwelling adults aged 18 years and older who were hospitalized to the acute medicine services at Northwestern Memorial Hospital and being discharged to their home. The patients recruited had PCPs from practices in the Research and Education for Academic Achievement (REACH) Practice‐Based Research Network. The REACH Practice‐Based Research Network consists of 8 academic, private, and community‐based provider groups affiliated with Northwestern Memorial Hospital and the Northwestern University Feinberg School of Medicine. Subjects were excluded if they (1) were unable to consent to their own procedures while hospitalized, (2) were severely vision impaired that could not be corrected with glasses (because they would be administered tests requiring adequate vision), (3) were reliant on a caregiver or home aide services 8 hours or greater per day, (4) were enrolled in hospice, (5) spoke a language other than English or Spanish, (6) were expected to have a hospital length of stay of <24 hours, or (7) were on <5 outpatient medications prior to hospitalization.
Initial Patient InterviewHospital
Research staff conducted structured in‐person surveys of eligible hospitalized subjects in the private hospital rooms of subjects to maintain confidentiality. Subjects received $20 compensation for their participation. After written informed consent was obtained, research staff obtained demographic information from the subject as well as ascertained their availability in 48 hours, support system, medications, and PCP. Research staff then administered the Short Test of Functional Health Literacy in Adults (sTOFHLA) to determine health literacy.[13] All research staff received the same training on administering the cognitive testing. The survey lasted between 20 and 30 minutes. At hospital discharge, the medication list was obtained from the discharge instructions listed in the patient's electronic medical record.
The PCP‐Enhanced Discharge Communication Intervention
Research staff and the principal investigator met with hospitalists and REACH outpatient physicians in groups to inform them of the study prior to beginning. When the patient was nearing discharge from the hospital, hospitalists were asked to phone the PCP to discuss the patient's discharge plan and facilitate clinical handoffs to the outpatient setting. Research staff paged the hospitalists with the PCP's contact information and reminded them to contact the PCP. Following the hospitalistPCP phone call, the PCP contacted the patient within 24 hours of discharge, either in person while in the hospital or by phone at home. The PCP confirmed medications and clarified any posthospital confusion. The contact flexibility (phone or by person and within 24 hours) was planned as PCPs had other responsibilities that would not allow them to be present at the actual discharge. Physicians were asked to review medications and follow‐up plans, but phone conversations were not recorded. PCPs were given a laminated card that contained points to discuss on discharge (Figure 1). PCPs were compensated with a $5 coffee shop gift card for their time to call patients. This intervention did not involve any additional healthcare personnel.
Postdischarge Phone Interview
During the initial interview, research staff set up a time to contact the subject by phone at 48 hours postdischarge. Research staff contacted the subject at the scheduled time and attempted contact 3 times within 24 hours of scheduled time. During the phone interview, subjects were asked whether they had contact with their PCP to discuss hospital discharge instructions (if so, when) and how satisfied they were with the contact. The subject was also asked whether they were confused with any aspect of the discharge, and if they were, whether the PCP alleviated the confusion. The subjects were asked whether anyone has assisted with their medications, whether they had medication changes, and which medications they were currently taking in the outpatient setting. Both prescription and over‐the‐counter medications were included. Over‐the‐counter medications were included in the study to determine the severity of medication discrepancies if they existed.
The medication list given by the subject was compared with the medical record for the medication list at discharge. Research staff would determine if a discrepancy was present. A discrepancy was considered (1) omission of a medication prescribed at discharge, (2) addition of a medication that was not prescribed at discharge, (3) different dose, (4) different frequency, or (5) duplication of a medication. If discrepancies existed, the subjects were asked for the reason that the discrepancies may have occurred. If discrepancies were identified, subjects were asked to contact their PCP regarding any medication discrepancies and to clarify any issues about medications they had.
Data Analysis
Subjects were categorized into whether they were contacted or not contacted by the PCP within 48 hours of discharge from the hospital. Those who were contacted were defined as those who saw a PCP in person at the time of discharge or within 48 hours of discharge or were called within 48 hours. Those who had an appointment with a PCP after 48 hours of discharge, saw a PCP while hospitalized but did not discuss discharge plan, saw a specialist (such as allergist, urologist, wound care specialist), or who spoke to their PCP but did not discuss their discharge plan were categorized as not contacted.
Reasons for medication discrepancies were categorized into patient‐associated factors (adverse drug effect, intentional nonadherence, unintentional nonadherence) and system‐associated factors (confusion between brand and generic names, discharge instruction incomplete or inaccurate, duplication, incorrect dosage) according to a published medication discrepancy tool.[2] Discrepancies were categorized as intentional nonadherence if patients knew the regimen but decided not to adhere. On the other hand, unintentional nonadherence was used for discrepancies in which patients were unaware of the regimen and thus the discrepancy. Medication discrepancies were classified as mild, moderate, or severe depending on the medication involved. Mild discrepancies were over‐the‐counter medications (eg, acetaminophen, laxatives, multivitamins) and topical creams. Severe discrepancies included medications for heart disease (eg, ‐blockers, calcium channel blockers, angiotensin receptor blockers, diuretics), pulmonary disease (eg, inhalers), diabetes (eg, insulin, glyburide), and antibiotics. Moderate discrepancies were those that did not fit the mild or severe categories (eg, prescription pain medication such as narcotics, anxiety medications, bisphosphonates, muscle relaxants).
Statistical analysis was performed with the SPSS 18.0 (SPSS Inc., Chicago, IL). We analyzed data on study patients to estimate the effect of contact with the PCP within 48 hours of discharge on the frequency of any medication discrepancy. We first examined differences between patients who were contacted or not contacted by patient sociodemographic characteristics. [2] tests were used to analyze the significance of differences in the proportion of medication discrepancies between patients who were contacted and not contacted. Logistic regression analysis was used to test the effect of being contacted on the likelihood of having any prescription medication discrepancy after controlling for patient characteristics (eg, race and ethnicity, age, number of medications, living alone, sex, and TOFHLA score.)
RESULTS
Sample Characteristics
Of the 225 patients who met inclusion criteria, 114 subjects were recruited and interviewed by research staff during the hospital stay and 48 hours after discharge. Due to early discharge and staffing reasons, 27 subjects were not able to be approached during discharge. Of the 84 patients who declined the study, the reasons included: not interested in study (n=58), did not feel well enough to complete or participate (n=16), did not wish study personnel to have access to personal records (n=5), and no reason given (n=5). Of the 114 subjects enrolled in the hospital, 77 subjects completed 48‐hour postdischarge phone interviews with research staff. Two patients had missing data, leaving 75 patients who were included in the analysis.
Study patients' age, race and ethnicity, sex, living situation (alone vs not alone), number of medications, mean sTOFHLA score, and medication discrepancy are summarized in Table 1. Thirty‐six percent of patients (n=27) were contacted by the PCP within 48 hours of discharge. Age, living situation (alone vs not alone), number of medications, and mean sTOFHLA score were similar in both groups of contacted versus noncontacted patients. Of those who were contacted, males made up 48.1% versus 27.1% for those not contacted (P=0.06). Similarly, 44.4% of those who were not contacted were black versus 37.5% among the contacted (P=0.035).
| All Subjects, N=77 | Subject Without PCP Contact, n=50 | Subjects With PCP Contact, n=27 | P Value | |
|---|---|---|---|---|
| ||||
| Mean ageSD, y | 63.012.2 | 63.311.9 | 62.313.1 | 0.74 |
| Race and ethnicity, n (%) | 0.35 | |||
| White/other | 40 (53.5) | 28 (58.3) | 12 (44.4) | |
| Black | 30 (40.0) | 18 (37.5) | 12 (44.4) | |
| Hispanic | 5 (6.7) | 2 (4.2) | 3 (11.1) | |
| Male, n (%) | 26 (34.7) | 13 (27.1) | 13 (48.1) | 0.06 |
| Lives alone, n (%) | 30 (40.0) | 20 (41.7) | 10 (37.0) | 0.69 |
| Mean sTOFHLA scoreSD | 29.67.9 | 29.47.7 | 29.97.8 | 0.75 |
| Mean number of medications | 9.224.9 | 9.064.7 | 9.633.5 | 0.67 |
| Experienced medication discrepancy, n (%) | 39 (52) | 28 (59.3) | 11 (40.7) | 0.14 |
Medication Discrepancies
Of the 75 study patients, 39 patients (50.6%) experienced a total of 84 medication discrepancies. Fifty‐eight medication discrepancies were prescription medications, whereas 25 were over‐the‐counter medications. Of those who had discrepancies, 46.2% (n=18) had 1 discrepancy, 23.1% (n=9) had 2 discrepancies, 12.8% (n=5) had 3 discrepancies, 10.2% (n=4) had 4 discrepancies, and 7.7% (n=3) 5 or more discrepancies. The mean number of discrepancies per patient was 2.15 per patient. Medication discrepancies were categorized by severity based on the safety profile of the medication involved and type discrepancy (Table 2).
| Frequency, n (%) | |
|---|---|
| |
| Type of medication discrepancy | |
| Over the counter | 26 (30.9) |
| Prescription medication | 58 (69.0) |
| Severity of medication discrepancy | |
| Milda | 28 (33.3) |
| Moderateb | 24 (28.6) |
| Severec | 32 (38.1) |
Reasons for Medication Discrepancies
The subject‐provided reasons for medication discrepancies are listed in Table 3 and divided into patient‐ and system‐associated factors. The overall most frequent reason for a discrepancy was the patient's intentional nonadherence. Examples of intentional nonadherence include not sure of purpose of medication, did not recognize drug, did not fill prescription, did not need prescription, and wanted to wait longer, so not taking diuretic daily. The second most frequent reason was inaccurate discharge instructions (e.g., discharge instructions with medication changes denoting no change but incorrect outpatient thyroid medication dosage listed (Table 3).
| Factor | Frequency, n (%) |
|---|---|
| Patient‐associated factors | |
| Adverse drug effects | 8 (9.5) |
| Intentional nonadherence | 50 (59.4) |
| Unintentional nonadherence | 1 (1.2) |
| Subtotal | 59 |
| System‐associated factors | |
| Confusion between brand and generic names | 3 (3.5) |
| Discharge Instructions incomplete or inaccurate | 12 (14.2) |
| Duplication | 3 (3.5) |
| Incorrect dosage | 3 (3.5) |
| Incorrect frequency | 1 (1.2) |
| Conflicting information from different sources | 3 (3.5) |
| Subtotal | 25 |
| Total | 84 |
Logistic Regression Results for the Likelihood of Any Medication Discrepancy
Logistical regression results are shown in Table 4. Patients who were contacted by their PCP at discharge were 70% less likely to have a discrepancy when compared with those who were not contacted (P=0.03). This result was controlled for other possible factors including patient sex. Of interest, men were 3.94 times more likely to have a discrepancy when compared with women (P=0.02). There was also a nonsignificant but potentially important association between higher health literacy, measured continuously (0X) and being more likely to have a discrepancy (P=0.07). Including variables for age, ethnicity, and living alone were nonsignificant and did not change the regression results for contacted patients.
| Odds Ratio | 95% Confidence Interval | |
|---|---|---|
| ||
| Subject contacted by PCP at Discharge | 0.33 | 0.110.97 |
| Male | 3.98 | 1.2712.49 |
| Number of medications | 1.09 | 0.961.23 |
| TOHFLA score | 1.09 | 1.011.18 |
DISCUSSION
Our results provide evidence that contact with PCPs within 24 hours of hospital discharge can be effective in decreasing medication discrepancies. The PCP‐Enhanced Discharge Communication Intervention was designed to investigate the value of improving existing lines of communication at discharge without involving any additional healthcare personnel. As a lean discharge intervention, the PCP, the hospitalist, and the patient were the main components to this intervention.
This study was limited in that the sample size was small and that we enrolled consecutive patients. Due to the small sample size, we did not examine hospital readmissions. Further studies are needed to examine whether primary care involvement at discharge would affect hospital readmissions. Another limitation of this study was that the control group was not randomized or preselected. Our study compared those subjects who received a phone call from their PCP to those subjects who did not. Although we instructed PCPs with a standardized script, we did not record or ensure that the phone call‐up occurred as such. There is potential variability in how the PCPs conducted their follow‐up with patients, and we are unable to measure what was effective and ineffective in reducing medication discrepancies. Another limitation was that the determination of the severity of the medication discrepancy was done by medication involved as opposed to by physician review and adjudication. The study would have been strengthened by interviewing the outpatient physicians on the amount of harm each discrepancy would or did cause the patient.
The most frequent reason for discrepancy was intentional nonadherence. Prior research has shown that intentional nonadherence of medications at hospital discharge is linked to health literacy.[14] One may postulate that patients with adequate health literacy feel enabled to go against medical advice and chose to not take medications as prescribed.
In our study, patients had the most medication discrepancies in the severe medications category, which involved cardiac, pulmonary, and diabetic medications, compared with the mild and moderate category. This finding may reflect the frequency that these medications are prescribed but are consistent with findings of Coleman et al.[2] The finding highlights the need to ensure adequate education and understanding of medication regimens for these complex patients. Patients with cardiac, pulmonary, and diabetic disease may benefit from personalized discharge instructions and a more structured and organized medication reconciliation process.
Our study found that males were more likely to have a medication discrepancy than females, which has not been found in previous studies on medication discrepancies. One study on Medicare beneficiaries with congestive heart failure found that men were much more likely to be readmitted than woman within 6 months of discharge.[15] The reason for the increased risk of medication discrepancy in males is unknown. Gender differences in health have frequently been reported, with men having higher rates of morbidity and mortality than women.[16, 17] The differences are thought to be due to the reluctance of men to seek medical help and consult medical practitioners when needed. It has been known that women use health services more than men, and are more likely than men to report a chronic illness.[18] When men do present with symptoms, it is often later in the stage of a disease than women and when treatment is less likely to be successful.[19] It may be that men in this study population had more medication discrepancies as they were reluctant to seek help or ask for clarification regarding medications at discharge.
Of those enrolled, 36% of patients were contacted by their PCP within 48 hours of discharge. It is unclear if the PCP attempted but was unable to reach the patient or did not attempt to call the patient. Although PCPs were compensated with a $5 coffee shop gift card, a larger compensation may insure completion of the patient contact. Further research is needed to determine the reasons why PCPs were not able to complete the phone call.
From a policy standpoint, hospitals that focus solely on hospital‐based transition interventions are potentially missing half the problem. The hospital acts as a sender or pitcher, and the PCP acts as a receiver or catcher. The receiver needs to be included in the discharge process for a successful patient transition to home. With recent billing changes for transition coding, the Center for Medicare and Medicaid Services recognizes this relationship.[20] Outpatient PCPs are able to bill for bundled follow‐up phone calls and appointments. Instead of paying additional staff to make 48‐hour postdischarge phone calls, hospitals should consider partnering with PCPs to ensure a more organized discharge.
Our results showed that PCP communication with patients within 24 hours of discharge was associated with decreased medication discrepancies. The PCP is vital to ensuring a safe transition home from the hospital. Because many patients have an established relationship with their PCP, a bond of trust exists that is often missing with hospital‐employed transitional staff. Patients pay attention when a known physician contacts them directly. In our study, patients may have felt comfortable addressing their concerns and questions with their trusted PCP. Subsequently, patients may have been more attuned to the answers their PCP gave and avoided medication errors. Our results further demonstrate the importance of PCP involvement in the hospital discharge process to improve the care of our patients.
- , , , , . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161–167.
- , , , . Posthospital medication discrepancies—prevalence and contributing factors. Arch Intern Med. 2005;165(16):1842–1847.
- , , , et al. Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med. 1994;120(12):999–1006.
- , , , , . Further application of the care transitions intervention: results of a randomized controlled trial conducted in a fee‐for‐service setting. Home Health Care Serv Q. 2009;28(2‐3):84–99.
- , , . Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334(22):1441–1446.
- , , , et al. Reduction of 30‐day postdischarge hospital readmission or emergency department (ED) visit rates in high‐risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009;4(4):211–218.
- , , , et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178–187.
- , , , , . A case manager intervention to reduce readmissions. Arch Intern Med. 1994;154(15):1721–1729.
- , , , , , . Preparing patients and caregivers to participate in care delivered across settings: the Care Transitions Intervention. J Am Geriatr Soc. 2004;52(11):1817–1825.
- , , , et al. Effect of a nurse team coordinator on outcomes for hospitalized medicine patients. Am J Med. 2005;118(10):1148–1153.
- , , , et al. Problems after discharge and understanding of communication with their primary care physicians among hospitalized seniors: a mixed methods study. J Hosp Med. 2010;5(7):385–391.
- , . Hospital readmissions in the Medicare population. N Engl J Med. 1984;311(21):1349–1353.
- , , , , . Development of a brief test to measure functional health literacy. Patient Educ Couns. 1999;38(1):33–42.
- , , , , , . Relationship of Health Literacy to Intentional and Unintentional Non‐Adherence of Hospital Discharge Medications. J Gen Intern Med. 2012;27(2):173–178.
- , , , et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157(1):99–104.
- . College men's health: an overview and a call to action. J Am Coll Health. 1998;46(6):279–290.
- Gender and the Social Construction of Illness. Thousand Oaks, CA: Sage; 1997.
- Inequalities in Health: The Black Report and the Health Divide. London, UK: Penguin; 1988.
- , , , . Decision making process in people with symptoms of acute myocardial infarction: qualitative study. BMJ. 2002;332:1006–1017.
- Centers for Medicare and Medicaid Services. Transitional Care Management Services. Available at: http://www.cms.gov/Medicare/Medicare‐Fee‐for‐Service‐Payment/PhysicianFeeSched/Downloads/FAQ‐TCMS.pdf. Accessed June 28, 2013.
Medication errors occur frequently when patients transition care between providers, such as the transition from hospital to home.[1] Approximately 50% of about 3 million adults per year over 65 years of age transitioning from hospital to home experience a medication discrepancy.[1] At hospital discharge, patients with complex medical problems are prescribed multiple medications with complex dosing and schedules. To add to this complexity, many patients also have cognitive impairment, variable health literacy, and limited social and financial support. Patients with medication discrepancies have significantly higher rates of rehospitalization compared to those without medication discrepancies.[2] Thus, interventions that focus on patients at greater risk of medication discrepancies may identify those at greater risk of subsequent rehospitalization and potentially reduce the rates of readmissions.[3]
There is limited evidence to date on the effectiveness of interventions to decrease post‐hospitalization medication discrepancies.[3, 4, 5, 6] Previous transitional care interventions have been expensive and difficult to sustain due to the need for multiple additional transitional care personnel (e.g., care managers, nurses, pharmacists, transitional care coaches).[7, 8, 9, 10] Moreover, these additional personnel may further fragment the care of hospitalized patients with additional handoffs.
As both hospitalists and outpatient primary care physicians (PCPs) are being expected to care for larger numbers of increasingly sicker patients, the communication handoff of patient information at discharge remains a challenge.[11] Both patients and PCPs often obtain incomplete or inaccurate information and instructions at discharge. Follow‐up appointments are often missed or delayed.[12] Many hospital‐based interventions do not directly involve the PCP or take advantage of the already established PCPpatient relationship.
We conducted a pilot study examining whether enhancing PCP communication with patients at hospital discharge would impact medication discrepancies and improve the safety of the patient as they transitioned home from the hospital.
METHODS
Recruitment of Subjects
The institutional review board of Northwestern University approved this study. Accessing the hospital electronic health record, research staff queried admission information and contacted the hospital physician to determine potential subject eligibility. Research staff recruited consecutive community‐dwelling adults aged 18 years and older who were hospitalized to the acute medicine services at Northwestern Memorial Hospital and being discharged to their home. The patients recruited had PCPs from practices in the Research and Education for Academic Achievement (REACH) Practice‐Based Research Network. The REACH Practice‐Based Research Network consists of 8 academic, private, and community‐based provider groups affiliated with Northwestern Memorial Hospital and the Northwestern University Feinberg School of Medicine. Subjects were excluded if they (1) were unable to consent to their own procedures while hospitalized, (2) were severely vision impaired that could not be corrected with glasses (because they would be administered tests requiring adequate vision), (3) were reliant on a caregiver or home aide services 8 hours or greater per day, (4) were enrolled in hospice, (5) spoke a language other than English or Spanish, (6) were expected to have a hospital length of stay of <24 hours, or (7) were on <5 outpatient medications prior to hospitalization.
Initial Patient InterviewHospital
Research staff conducted structured in‐person surveys of eligible hospitalized subjects in the private hospital rooms of subjects to maintain confidentiality. Subjects received $20 compensation for their participation. After written informed consent was obtained, research staff obtained demographic information from the subject as well as ascertained their availability in 48 hours, support system, medications, and PCP. Research staff then administered the Short Test of Functional Health Literacy in Adults (sTOFHLA) to determine health literacy.[13] All research staff received the same training on administering the cognitive testing. The survey lasted between 20 and 30 minutes. At hospital discharge, the medication list was obtained from the discharge instructions listed in the patient's electronic medical record.
The PCP‐Enhanced Discharge Communication Intervention
Research staff and the principal investigator met with hospitalists and REACH outpatient physicians in groups to inform them of the study prior to beginning. When the patient was nearing discharge from the hospital, hospitalists were asked to phone the PCP to discuss the patient's discharge plan and facilitate clinical handoffs to the outpatient setting. Research staff paged the hospitalists with the PCP's contact information and reminded them to contact the PCP. Following the hospitalistPCP phone call, the PCP contacted the patient within 24 hours of discharge, either in person while in the hospital or by phone at home. The PCP confirmed medications and clarified any posthospital confusion. The contact flexibility (phone or by person and within 24 hours) was planned as PCPs had other responsibilities that would not allow them to be present at the actual discharge. Physicians were asked to review medications and follow‐up plans, but phone conversations were not recorded. PCPs were given a laminated card that contained points to discuss on discharge (Figure 1). PCPs were compensated with a $5 coffee shop gift card for their time to call patients. This intervention did not involve any additional healthcare personnel.
Postdischarge Phone Interview
During the initial interview, research staff set up a time to contact the subject by phone at 48 hours postdischarge. Research staff contacted the subject at the scheduled time and attempted contact 3 times within 24 hours of scheduled time. During the phone interview, subjects were asked whether they had contact with their PCP to discuss hospital discharge instructions (if so, when) and how satisfied they were with the contact. The subject was also asked whether they were confused with any aspect of the discharge, and if they were, whether the PCP alleviated the confusion. The subjects were asked whether anyone has assisted with their medications, whether they had medication changes, and which medications they were currently taking in the outpatient setting. Both prescription and over‐the‐counter medications were included. Over‐the‐counter medications were included in the study to determine the severity of medication discrepancies if they existed.
The medication list given by the subject was compared with the medical record for the medication list at discharge. Research staff would determine if a discrepancy was present. A discrepancy was considered (1) omission of a medication prescribed at discharge, (2) addition of a medication that was not prescribed at discharge, (3) different dose, (4) different frequency, or (5) duplication of a medication. If discrepancies existed, the subjects were asked for the reason that the discrepancies may have occurred. If discrepancies were identified, subjects were asked to contact their PCP regarding any medication discrepancies and to clarify any issues about medications they had.
Data Analysis
Subjects were categorized into whether they were contacted or not contacted by the PCP within 48 hours of discharge from the hospital. Those who were contacted were defined as those who saw a PCP in person at the time of discharge or within 48 hours of discharge or were called within 48 hours. Those who had an appointment with a PCP after 48 hours of discharge, saw a PCP while hospitalized but did not discuss discharge plan, saw a specialist (such as allergist, urologist, wound care specialist), or who spoke to their PCP but did not discuss their discharge plan were categorized as not contacted.
Reasons for medication discrepancies were categorized into patient‐associated factors (adverse drug effect, intentional nonadherence, unintentional nonadherence) and system‐associated factors (confusion between brand and generic names, discharge instruction incomplete or inaccurate, duplication, incorrect dosage) according to a published medication discrepancy tool.[2] Discrepancies were categorized as intentional nonadherence if patients knew the regimen but decided not to adhere. On the other hand, unintentional nonadherence was used for discrepancies in which patients were unaware of the regimen and thus the discrepancy. Medication discrepancies were classified as mild, moderate, or severe depending on the medication involved. Mild discrepancies were over‐the‐counter medications (eg, acetaminophen, laxatives, multivitamins) and topical creams. Severe discrepancies included medications for heart disease (eg, ‐blockers, calcium channel blockers, angiotensin receptor blockers, diuretics), pulmonary disease (eg, inhalers), diabetes (eg, insulin, glyburide), and antibiotics. Moderate discrepancies were those that did not fit the mild or severe categories (eg, prescription pain medication such as narcotics, anxiety medications, bisphosphonates, muscle relaxants).
Statistical analysis was performed with the SPSS 18.0 (SPSS Inc., Chicago, IL). We analyzed data on study patients to estimate the effect of contact with the PCP within 48 hours of discharge on the frequency of any medication discrepancy. We first examined differences between patients who were contacted or not contacted by patient sociodemographic characteristics. [2] tests were used to analyze the significance of differences in the proportion of medication discrepancies between patients who were contacted and not contacted. Logistic regression analysis was used to test the effect of being contacted on the likelihood of having any prescription medication discrepancy after controlling for patient characteristics (eg, race and ethnicity, age, number of medications, living alone, sex, and TOFHLA score.)
RESULTS
Sample Characteristics
Of the 225 patients who met inclusion criteria, 114 subjects were recruited and interviewed by research staff during the hospital stay and 48 hours after discharge. Due to early discharge and staffing reasons, 27 subjects were not able to be approached during discharge. Of the 84 patients who declined the study, the reasons included: not interested in study (n=58), did not feel well enough to complete or participate (n=16), did not wish study personnel to have access to personal records (n=5), and no reason given (n=5). Of the 114 subjects enrolled in the hospital, 77 subjects completed 48‐hour postdischarge phone interviews with research staff. Two patients had missing data, leaving 75 patients who were included in the analysis.
Study patients' age, race and ethnicity, sex, living situation (alone vs not alone), number of medications, mean sTOFHLA score, and medication discrepancy are summarized in Table 1. Thirty‐six percent of patients (n=27) were contacted by the PCP within 48 hours of discharge. Age, living situation (alone vs not alone), number of medications, and mean sTOFHLA score were similar in both groups of contacted versus noncontacted patients. Of those who were contacted, males made up 48.1% versus 27.1% for those not contacted (P=0.06). Similarly, 44.4% of those who were not contacted were black versus 37.5% among the contacted (P=0.035).
| All Subjects, N=77 | Subject Without PCP Contact, n=50 | Subjects With PCP Contact, n=27 | P Value | |
|---|---|---|---|---|
| ||||
| Mean ageSD, y | 63.012.2 | 63.311.9 | 62.313.1 | 0.74 |
| Race and ethnicity, n (%) | 0.35 | |||
| White/other | 40 (53.5) | 28 (58.3) | 12 (44.4) | |
| Black | 30 (40.0) | 18 (37.5) | 12 (44.4) | |
| Hispanic | 5 (6.7) | 2 (4.2) | 3 (11.1) | |
| Male, n (%) | 26 (34.7) | 13 (27.1) | 13 (48.1) | 0.06 |
| Lives alone, n (%) | 30 (40.0) | 20 (41.7) | 10 (37.0) | 0.69 |
| Mean sTOFHLA scoreSD | 29.67.9 | 29.47.7 | 29.97.8 | 0.75 |
| Mean number of medications | 9.224.9 | 9.064.7 | 9.633.5 | 0.67 |
| Experienced medication discrepancy, n (%) | 39 (52) | 28 (59.3) | 11 (40.7) | 0.14 |
Medication Discrepancies
Of the 75 study patients, 39 patients (50.6%) experienced a total of 84 medication discrepancies. Fifty‐eight medication discrepancies were prescription medications, whereas 25 were over‐the‐counter medications. Of those who had discrepancies, 46.2% (n=18) had 1 discrepancy, 23.1% (n=9) had 2 discrepancies, 12.8% (n=5) had 3 discrepancies, 10.2% (n=4) had 4 discrepancies, and 7.7% (n=3) 5 or more discrepancies. The mean number of discrepancies per patient was 2.15 per patient. Medication discrepancies were categorized by severity based on the safety profile of the medication involved and type discrepancy (Table 2).
| Frequency, n (%) | |
|---|---|
| |
| Type of medication discrepancy | |
| Over the counter | 26 (30.9) |
| Prescription medication | 58 (69.0) |
| Severity of medication discrepancy | |
| Milda | 28 (33.3) |
| Moderateb | 24 (28.6) |
| Severec | 32 (38.1) |
Reasons for Medication Discrepancies
The subject‐provided reasons for medication discrepancies are listed in Table 3 and divided into patient‐ and system‐associated factors. The overall most frequent reason for a discrepancy was the patient's intentional nonadherence. Examples of intentional nonadherence include not sure of purpose of medication, did not recognize drug, did not fill prescription, did not need prescription, and wanted to wait longer, so not taking diuretic daily. The second most frequent reason was inaccurate discharge instructions (e.g., discharge instructions with medication changes denoting no change but incorrect outpatient thyroid medication dosage listed (Table 3).
| Factor | Frequency, n (%) |
|---|---|
| Patient‐associated factors | |
| Adverse drug effects | 8 (9.5) |
| Intentional nonadherence | 50 (59.4) |
| Unintentional nonadherence | 1 (1.2) |
| Subtotal | 59 |
| System‐associated factors | |
| Confusion between brand and generic names | 3 (3.5) |
| Discharge Instructions incomplete or inaccurate | 12 (14.2) |
| Duplication | 3 (3.5) |
| Incorrect dosage | 3 (3.5) |
| Incorrect frequency | 1 (1.2) |
| Conflicting information from different sources | 3 (3.5) |
| Subtotal | 25 |
| Total | 84 |
Logistic Regression Results for the Likelihood of Any Medication Discrepancy
Logistical regression results are shown in Table 4. Patients who were contacted by their PCP at discharge were 70% less likely to have a discrepancy when compared with those who were not contacted (P=0.03). This result was controlled for other possible factors including patient sex. Of interest, men were 3.94 times more likely to have a discrepancy when compared with women (P=0.02). There was also a nonsignificant but potentially important association between higher health literacy, measured continuously (0X) and being more likely to have a discrepancy (P=0.07). Including variables for age, ethnicity, and living alone were nonsignificant and did not change the regression results for contacted patients.
| Odds Ratio | 95% Confidence Interval | |
|---|---|---|
| ||
| Subject contacted by PCP at Discharge | 0.33 | 0.110.97 |
| Male | 3.98 | 1.2712.49 |
| Number of medications | 1.09 | 0.961.23 |
| TOHFLA score | 1.09 | 1.011.18 |
DISCUSSION
Our results provide evidence that contact with PCPs within 24 hours of hospital discharge can be effective in decreasing medication discrepancies. The PCP‐Enhanced Discharge Communication Intervention was designed to investigate the value of improving existing lines of communication at discharge without involving any additional healthcare personnel. As a lean discharge intervention, the PCP, the hospitalist, and the patient were the main components to this intervention.
This study was limited in that the sample size was small and that we enrolled consecutive patients. Due to the small sample size, we did not examine hospital readmissions. Further studies are needed to examine whether primary care involvement at discharge would affect hospital readmissions. Another limitation of this study was that the control group was not randomized or preselected. Our study compared those subjects who received a phone call from their PCP to those subjects who did not. Although we instructed PCPs with a standardized script, we did not record or ensure that the phone call‐up occurred as such. There is potential variability in how the PCPs conducted their follow‐up with patients, and we are unable to measure what was effective and ineffective in reducing medication discrepancies. Another limitation was that the determination of the severity of the medication discrepancy was done by medication involved as opposed to by physician review and adjudication. The study would have been strengthened by interviewing the outpatient physicians on the amount of harm each discrepancy would or did cause the patient.
The most frequent reason for discrepancy was intentional nonadherence. Prior research has shown that intentional nonadherence of medications at hospital discharge is linked to health literacy.[14] One may postulate that patients with adequate health literacy feel enabled to go against medical advice and chose to not take medications as prescribed.
In our study, patients had the most medication discrepancies in the severe medications category, which involved cardiac, pulmonary, and diabetic medications, compared with the mild and moderate category. This finding may reflect the frequency that these medications are prescribed but are consistent with findings of Coleman et al.[2] The finding highlights the need to ensure adequate education and understanding of medication regimens for these complex patients. Patients with cardiac, pulmonary, and diabetic disease may benefit from personalized discharge instructions and a more structured and organized medication reconciliation process.
Our study found that males were more likely to have a medication discrepancy than females, which has not been found in previous studies on medication discrepancies. One study on Medicare beneficiaries with congestive heart failure found that men were much more likely to be readmitted than woman within 6 months of discharge.[15] The reason for the increased risk of medication discrepancy in males is unknown. Gender differences in health have frequently been reported, with men having higher rates of morbidity and mortality than women.[16, 17] The differences are thought to be due to the reluctance of men to seek medical help and consult medical practitioners when needed. It has been known that women use health services more than men, and are more likely than men to report a chronic illness.[18] When men do present with symptoms, it is often later in the stage of a disease than women and when treatment is less likely to be successful.[19] It may be that men in this study population had more medication discrepancies as they were reluctant to seek help or ask for clarification regarding medications at discharge.
Of those enrolled, 36% of patients were contacted by their PCP within 48 hours of discharge. It is unclear if the PCP attempted but was unable to reach the patient or did not attempt to call the patient. Although PCPs were compensated with a $5 coffee shop gift card, a larger compensation may insure completion of the patient contact. Further research is needed to determine the reasons why PCPs were not able to complete the phone call.
From a policy standpoint, hospitals that focus solely on hospital‐based transition interventions are potentially missing half the problem. The hospital acts as a sender or pitcher, and the PCP acts as a receiver or catcher. The receiver needs to be included in the discharge process for a successful patient transition to home. With recent billing changes for transition coding, the Center for Medicare and Medicaid Services recognizes this relationship.[20] Outpatient PCPs are able to bill for bundled follow‐up phone calls and appointments. Instead of paying additional staff to make 48‐hour postdischarge phone calls, hospitals should consider partnering with PCPs to ensure a more organized discharge.
Our results showed that PCP communication with patients within 24 hours of discharge was associated with decreased medication discrepancies. The PCP is vital to ensuring a safe transition home from the hospital. Because many patients have an established relationship with their PCP, a bond of trust exists that is often missing with hospital‐employed transitional staff. Patients pay attention when a known physician contacts them directly. In our study, patients may have felt comfortable addressing their concerns and questions with their trusted PCP. Subsequently, patients may have been more attuned to the answers their PCP gave and avoided medication errors. Our results further demonstrate the importance of PCP involvement in the hospital discharge process to improve the care of our patients.
Medication errors occur frequently when patients transition care between providers, such as the transition from hospital to home.[1] Approximately 50% of about 3 million adults per year over 65 years of age transitioning from hospital to home experience a medication discrepancy.[1] At hospital discharge, patients with complex medical problems are prescribed multiple medications with complex dosing and schedules. To add to this complexity, many patients also have cognitive impairment, variable health literacy, and limited social and financial support. Patients with medication discrepancies have significantly higher rates of rehospitalization compared to those without medication discrepancies.[2] Thus, interventions that focus on patients at greater risk of medication discrepancies may identify those at greater risk of subsequent rehospitalization and potentially reduce the rates of readmissions.[3]
There is limited evidence to date on the effectiveness of interventions to decrease post‐hospitalization medication discrepancies.[3, 4, 5, 6] Previous transitional care interventions have been expensive and difficult to sustain due to the need for multiple additional transitional care personnel (e.g., care managers, nurses, pharmacists, transitional care coaches).[7, 8, 9, 10] Moreover, these additional personnel may further fragment the care of hospitalized patients with additional handoffs.
As both hospitalists and outpatient primary care physicians (PCPs) are being expected to care for larger numbers of increasingly sicker patients, the communication handoff of patient information at discharge remains a challenge.[11] Both patients and PCPs often obtain incomplete or inaccurate information and instructions at discharge. Follow‐up appointments are often missed or delayed.[12] Many hospital‐based interventions do not directly involve the PCP or take advantage of the already established PCPpatient relationship.
We conducted a pilot study examining whether enhancing PCP communication with patients at hospital discharge would impact medication discrepancies and improve the safety of the patient as they transitioned home from the hospital.
METHODS
Recruitment of Subjects
The institutional review board of Northwestern University approved this study. Accessing the hospital electronic health record, research staff queried admission information and contacted the hospital physician to determine potential subject eligibility. Research staff recruited consecutive community‐dwelling adults aged 18 years and older who were hospitalized to the acute medicine services at Northwestern Memorial Hospital and being discharged to their home. The patients recruited had PCPs from practices in the Research and Education for Academic Achievement (REACH) Practice‐Based Research Network. The REACH Practice‐Based Research Network consists of 8 academic, private, and community‐based provider groups affiliated with Northwestern Memorial Hospital and the Northwestern University Feinberg School of Medicine. Subjects were excluded if they (1) were unable to consent to their own procedures while hospitalized, (2) were severely vision impaired that could not be corrected with glasses (because they would be administered tests requiring adequate vision), (3) were reliant on a caregiver or home aide services 8 hours or greater per day, (4) were enrolled in hospice, (5) spoke a language other than English or Spanish, (6) were expected to have a hospital length of stay of <24 hours, or (7) were on <5 outpatient medications prior to hospitalization.
Initial Patient InterviewHospital
Research staff conducted structured in‐person surveys of eligible hospitalized subjects in the private hospital rooms of subjects to maintain confidentiality. Subjects received $20 compensation for their participation. After written informed consent was obtained, research staff obtained demographic information from the subject as well as ascertained their availability in 48 hours, support system, medications, and PCP. Research staff then administered the Short Test of Functional Health Literacy in Adults (sTOFHLA) to determine health literacy.[13] All research staff received the same training on administering the cognitive testing. The survey lasted between 20 and 30 minutes. At hospital discharge, the medication list was obtained from the discharge instructions listed in the patient's electronic medical record.
The PCP‐Enhanced Discharge Communication Intervention
Research staff and the principal investigator met with hospitalists and REACH outpatient physicians in groups to inform them of the study prior to beginning. When the patient was nearing discharge from the hospital, hospitalists were asked to phone the PCP to discuss the patient's discharge plan and facilitate clinical handoffs to the outpatient setting. Research staff paged the hospitalists with the PCP's contact information and reminded them to contact the PCP. Following the hospitalistPCP phone call, the PCP contacted the patient within 24 hours of discharge, either in person while in the hospital or by phone at home. The PCP confirmed medications and clarified any posthospital confusion. The contact flexibility (phone or by person and within 24 hours) was planned as PCPs had other responsibilities that would not allow them to be present at the actual discharge. Physicians were asked to review medications and follow‐up plans, but phone conversations were not recorded. PCPs were given a laminated card that contained points to discuss on discharge (Figure 1). PCPs were compensated with a $5 coffee shop gift card for their time to call patients. This intervention did not involve any additional healthcare personnel.
Postdischarge Phone Interview
During the initial interview, research staff set up a time to contact the subject by phone at 48 hours postdischarge. Research staff contacted the subject at the scheduled time and attempted contact 3 times within 24 hours of scheduled time. During the phone interview, subjects were asked whether they had contact with their PCP to discuss hospital discharge instructions (if so, when) and how satisfied they were with the contact. The subject was also asked whether they were confused with any aspect of the discharge, and if they were, whether the PCP alleviated the confusion. The subjects were asked whether anyone has assisted with their medications, whether they had medication changes, and which medications they were currently taking in the outpatient setting. Both prescription and over‐the‐counter medications were included. Over‐the‐counter medications were included in the study to determine the severity of medication discrepancies if they existed.
The medication list given by the subject was compared with the medical record for the medication list at discharge. Research staff would determine if a discrepancy was present. A discrepancy was considered (1) omission of a medication prescribed at discharge, (2) addition of a medication that was not prescribed at discharge, (3) different dose, (4) different frequency, or (5) duplication of a medication. If discrepancies existed, the subjects were asked for the reason that the discrepancies may have occurred. If discrepancies were identified, subjects were asked to contact their PCP regarding any medication discrepancies and to clarify any issues about medications they had.
Data Analysis
Subjects were categorized into whether they were contacted or not contacted by the PCP within 48 hours of discharge from the hospital. Those who were contacted were defined as those who saw a PCP in person at the time of discharge or within 48 hours of discharge or were called within 48 hours. Those who had an appointment with a PCP after 48 hours of discharge, saw a PCP while hospitalized but did not discuss discharge plan, saw a specialist (such as allergist, urologist, wound care specialist), or who spoke to their PCP but did not discuss their discharge plan were categorized as not contacted.
Reasons for medication discrepancies were categorized into patient‐associated factors (adverse drug effect, intentional nonadherence, unintentional nonadherence) and system‐associated factors (confusion between brand and generic names, discharge instruction incomplete or inaccurate, duplication, incorrect dosage) according to a published medication discrepancy tool.[2] Discrepancies were categorized as intentional nonadherence if patients knew the regimen but decided not to adhere. On the other hand, unintentional nonadherence was used for discrepancies in which patients were unaware of the regimen and thus the discrepancy. Medication discrepancies were classified as mild, moderate, or severe depending on the medication involved. Mild discrepancies were over‐the‐counter medications (eg, acetaminophen, laxatives, multivitamins) and topical creams. Severe discrepancies included medications for heart disease (eg, ‐blockers, calcium channel blockers, angiotensin receptor blockers, diuretics), pulmonary disease (eg, inhalers), diabetes (eg, insulin, glyburide), and antibiotics. Moderate discrepancies were those that did not fit the mild or severe categories (eg, prescription pain medication such as narcotics, anxiety medications, bisphosphonates, muscle relaxants).
Statistical analysis was performed with the SPSS 18.0 (SPSS Inc., Chicago, IL). We analyzed data on study patients to estimate the effect of contact with the PCP within 48 hours of discharge on the frequency of any medication discrepancy. We first examined differences between patients who were contacted or not contacted by patient sociodemographic characteristics. [2] tests were used to analyze the significance of differences in the proportion of medication discrepancies between patients who were contacted and not contacted. Logistic regression analysis was used to test the effect of being contacted on the likelihood of having any prescription medication discrepancy after controlling for patient characteristics (eg, race and ethnicity, age, number of medications, living alone, sex, and TOFHLA score.)
RESULTS
Sample Characteristics
Of the 225 patients who met inclusion criteria, 114 subjects were recruited and interviewed by research staff during the hospital stay and 48 hours after discharge. Due to early discharge and staffing reasons, 27 subjects were not able to be approached during discharge. Of the 84 patients who declined the study, the reasons included: not interested in study (n=58), did not feel well enough to complete or participate (n=16), did not wish study personnel to have access to personal records (n=5), and no reason given (n=5). Of the 114 subjects enrolled in the hospital, 77 subjects completed 48‐hour postdischarge phone interviews with research staff. Two patients had missing data, leaving 75 patients who were included in the analysis.
Study patients' age, race and ethnicity, sex, living situation (alone vs not alone), number of medications, mean sTOFHLA score, and medication discrepancy are summarized in Table 1. Thirty‐six percent of patients (n=27) were contacted by the PCP within 48 hours of discharge. Age, living situation (alone vs not alone), number of medications, and mean sTOFHLA score were similar in both groups of contacted versus noncontacted patients. Of those who were contacted, males made up 48.1% versus 27.1% for those not contacted (P=0.06). Similarly, 44.4% of those who were not contacted were black versus 37.5% among the contacted (P=0.035).
| All Subjects, N=77 | Subject Without PCP Contact, n=50 | Subjects With PCP Contact, n=27 | P Value | |
|---|---|---|---|---|
| ||||
| Mean ageSD, y | 63.012.2 | 63.311.9 | 62.313.1 | 0.74 |
| Race and ethnicity, n (%) | 0.35 | |||
| White/other | 40 (53.5) | 28 (58.3) | 12 (44.4) | |
| Black | 30 (40.0) | 18 (37.5) | 12 (44.4) | |
| Hispanic | 5 (6.7) | 2 (4.2) | 3 (11.1) | |
| Male, n (%) | 26 (34.7) | 13 (27.1) | 13 (48.1) | 0.06 |
| Lives alone, n (%) | 30 (40.0) | 20 (41.7) | 10 (37.0) | 0.69 |
| Mean sTOFHLA scoreSD | 29.67.9 | 29.47.7 | 29.97.8 | 0.75 |
| Mean number of medications | 9.224.9 | 9.064.7 | 9.633.5 | 0.67 |
| Experienced medication discrepancy, n (%) | 39 (52) | 28 (59.3) | 11 (40.7) | 0.14 |
Medication Discrepancies
Of the 75 study patients, 39 patients (50.6%) experienced a total of 84 medication discrepancies. Fifty‐eight medication discrepancies were prescription medications, whereas 25 were over‐the‐counter medications. Of those who had discrepancies, 46.2% (n=18) had 1 discrepancy, 23.1% (n=9) had 2 discrepancies, 12.8% (n=5) had 3 discrepancies, 10.2% (n=4) had 4 discrepancies, and 7.7% (n=3) 5 or more discrepancies. The mean number of discrepancies per patient was 2.15 per patient. Medication discrepancies were categorized by severity based on the safety profile of the medication involved and type discrepancy (Table 2).
| Frequency, n (%) | |
|---|---|
| |
| Type of medication discrepancy | |
| Over the counter | 26 (30.9) |
| Prescription medication | 58 (69.0) |
| Severity of medication discrepancy | |
| Milda | 28 (33.3) |
| Moderateb | 24 (28.6) |
| Severec | 32 (38.1) |
Reasons for Medication Discrepancies
The subject‐provided reasons for medication discrepancies are listed in Table 3 and divided into patient‐ and system‐associated factors. The overall most frequent reason for a discrepancy was the patient's intentional nonadherence. Examples of intentional nonadherence include not sure of purpose of medication, did not recognize drug, did not fill prescription, did not need prescription, and wanted to wait longer, so not taking diuretic daily. The second most frequent reason was inaccurate discharge instructions (e.g., discharge instructions with medication changes denoting no change but incorrect outpatient thyroid medication dosage listed (Table 3).
| Factor | Frequency, n (%) |
|---|---|
| Patient‐associated factors | |
| Adverse drug effects | 8 (9.5) |
| Intentional nonadherence | 50 (59.4) |
| Unintentional nonadherence | 1 (1.2) |
| Subtotal | 59 |
| System‐associated factors | |
| Confusion between brand and generic names | 3 (3.5) |
| Discharge Instructions incomplete or inaccurate | 12 (14.2) |
| Duplication | 3 (3.5) |
| Incorrect dosage | 3 (3.5) |
| Incorrect frequency | 1 (1.2) |
| Conflicting information from different sources | 3 (3.5) |
| Subtotal | 25 |
| Total | 84 |
Logistic Regression Results for the Likelihood of Any Medication Discrepancy
Logistical regression results are shown in Table 4. Patients who were contacted by their PCP at discharge were 70% less likely to have a discrepancy when compared with those who were not contacted (P=0.03). This result was controlled for other possible factors including patient sex. Of interest, men were 3.94 times more likely to have a discrepancy when compared with women (P=0.02). There was also a nonsignificant but potentially important association between higher health literacy, measured continuously (0X) and being more likely to have a discrepancy (P=0.07). Including variables for age, ethnicity, and living alone were nonsignificant and did not change the regression results for contacted patients.
| Odds Ratio | 95% Confidence Interval | |
|---|---|---|
| ||
| Subject contacted by PCP at Discharge | 0.33 | 0.110.97 |
| Male | 3.98 | 1.2712.49 |
| Number of medications | 1.09 | 0.961.23 |
| TOHFLA score | 1.09 | 1.011.18 |
DISCUSSION
Our results provide evidence that contact with PCPs within 24 hours of hospital discharge can be effective in decreasing medication discrepancies. The PCP‐Enhanced Discharge Communication Intervention was designed to investigate the value of improving existing lines of communication at discharge without involving any additional healthcare personnel. As a lean discharge intervention, the PCP, the hospitalist, and the patient were the main components to this intervention.
This study was limited in that the sample size was small and that we enrolled consecutive patients. Due to the small sample size, we did not examine hospital readmissions. Further studies are needed to examine whether primary care involvement at discharge would affect hospital readmissions. Another limitation of this study was that the control group was not randomized or preselected. Our study compared those subjects who received a phone call from their PCP to those subjects who did not. Although we instructed PCPs with a standardized script, we did not record or ensure that the phone call‐up occurred as such. There is potential variability in how the PCPs conducted their follow‐up with patients, and we are unable to measure what was effective and ineffective in reducing medication discrepancies. Another limitation was that the determination of the severity of the medication discrepancy was done by medication involved as opposed to by physician review and adjudication. The study would have been strengthened by interviewing the outpatient physicians on the amount of harm each discrepancy would or did cause the patient.
The most frequent reason for discrepancy was intentional nonadherence. Prior research has shown that intentional nonadherence of medications at hospital discharge is linked to health literacy.[14] One may postulate that patients with adequate health literacy feel enabled to go against medical advice and chose to not take medications as prescribed.
In our study, patients had the most medication discrepancies in the severe medications category, which involved cardiac, pulmonary, and diabetic medications, compared with the mild and moderate category. This finding may reflect the frequency that these medications are prescribed but are consistent with findings of Coleman et al.[2] The finding highlights the need to ensure adequate education and understanding of medication regimens for these complex patients. Patients with cardiac, pulmonary, and diabetic disease may benefit from personalized discharge instructions and a more structured and organized medication reconciliation process.
Our study found that males were more likely to have a medication discrepancy than females, which has not been found in previous studies on medication discrepancies. One study on Medicare beneficiaries with congestive heart failure found that men were much more likely to be readmitted than woman within 6 months of discharge.[15] The reason for the increased risk of medication discrepancy in males is unknown. Gender differences in health have frequently been reported, with men having higher rates of morbidity and mortality than women.[16, 17] The differences are thought to be due to the reluctance of men to seek medical help and consult medical practitioners when needed. It has been known that women use health services more than men, and are more likely than men to report a chronic illness.[18] When men do present with symptoms, it is often later in the stage of a disease than women and when treatment is less likely to be successful.[19] It may be that men in this study population had more medication discrepancies as they were reluctant to seek help or ask for clarification regarding medications at discharge.
Of those enrolled, 36% of patients were contacted by their PCP within 48 hours of discharge. It is unclear if the PCP attempted but was unable to reach the patient or did not attempt to call the patient. Although PCPs were compensated with a $5 coffee shop gift card, a larger compensation may insure completion of the patient contact. Further research is needed to determine the reasons why PCPs were not able to complete the phone call.
From a policy standpoint, hospitals that focus solely on hospital‐based transition interventions are potentially missing half the problem. The hospital acts as a sender or pitcher, and the PCP acts as a receiver or catcher. The receiver needs to be included in the discharge process for a successful patient transition to home. With recent billing changes for transition coding, the Center for Medicare and Medicaid Services recognizes this relationship.[20] Outpatient PCPs are able to bill for bundled follow‐up phone calls and appointments. Instead of paying additional staff to make 48‐hour postdischarge phone calls, hospitals should consider partnering with PCPs to ensure a more organized discharge.
Our results showed that PCP communication with patients within 24 hours of discharge was associated with decreased medication discrepancies. The PCP is vital to ensuring a safe transition home from the hospital. Because many patients have an established relationship with their PCP, a bond of trust exists that is often missing with hospital‐employed transitional staff. Patients pay attention when a known physician contacts them directly. In our study, patients may have felt comfortable addressing their concerns and questions with their trusted PCP. Subsequently, patients may have been more attuned to the answers their PCP gave and avoided medication errors. Our results further demonstrate the importance of PCP involvement in the hospital discharge process to improve the care of our patients.
- , , , , . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161–167.
- , , , . Posthospital medication discrepancies—prevalence and contributing factors. Arch Intern Med. 2005;165(16):1842–1847.
- , , , et al. Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med. 1994;120(12):999–1006.
- , , , , . Further application of the care transitions intervention: results of a randomized controlled trial conducted in a fee‐for‐service setting. Home Health Care Serv Q. 2009;28(2‐3):84–99.
- , , . Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334(22):1441–1446.
- , , , et al. Reduction of 30‐day postdischarge hospital readmission or emergency department (ED) visit rates in high‐risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009;4(4):211–218.
- , , , et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178–187.
- , , , , . A case manager intervention to reduce readmissions. Arch Intern Med. 1994;154(15):1721–1729.
- , , , , , . Preparing patients and caregivers to participate in care delivered across settings: the Care Transitions Intervention. J Am Geriatr Soc. 2004;52(11):1817–1825.
- , , , et al. Effect of a nurse team coordinator on outcomes for hospitalized medicine patients. Am J Med. 2005;118(10):1148–1153.
- , , , et al. Problems after discharge and understanding of communication with their primary care physicians among hospitalized seniors: a mixed methods study. J Hosp Med. 2010;5(7):385–391.
- , . Hospital readmissions in the Medicare population. N Engl J Med. 1984;311(21):1349–1353.
- , , , , . Development of a brief test to measure functional health literacy. Patient Educ Couns. 1999;38(1):33–42.
- , , , , , . Relationship of Health Literacy to Intentional and Unintentional Non‐Adherence of Hospital Discharge Medications. J Gen Intern Med. 2012;27(2):173–178.
- , , , et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157(1):99–104.
- . College men's health: an overview and a call to action. J Am Coll Health. 1998;46(6):279–290.
- Gender and the Social Construction of Illness. Thousand Oaks, CA: Sage; 1997.
- Inequalities in Health: The Black Report and the Health Divide. London, UK: Penguin; 1988.
- , , , . Decision making process in people with symptoms of acute myocardial infarction: qualitative study. BMJ. 2002;332:1006–1017.
- Centers for Medicare and Medicaid Services. Transitional Care Management Services. Available at: http://www.cms.gov/Medicare/Medicare‐Fee‐for‐Service‐Payment/PhysicianFeeSched/Downloads/FAQ‐TCMS.pdf. Accessed June 28, 2013.
- , , , , . The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003;138(3):161–167.
- , , , . Posthospital medication discrepancies—prevalence and contributing factors. Arch Intern Med. 2005;165(16):1842–1847.
- , , , et al. Comprehensive discharge planning for the hospitalized elderly. A randomized clinical trial. Ann Intern Med. 1994;120(12):999–1006.
- , , , , . Further application of the care transitions intervention: results of a randomized controlled trial conducted in a fee‐for‐service setting. Home Health Care Serv Q. 2009;28(2‐3):84–99.
- , , . Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. N Engl J Med. 1996;334(22):1441–1446.
- , , , et al. Reduction of 30‐day postdischarge hospital readmission or emergency department (ED) visit rates in high‐risk elderly medical patients through delivery of a targeted care bundle. J Hosp Med. 2009;4(4):211–218.
- , , , et al. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009;150(3):178–187.
- , , , , . A case manager intervention to reduce readmissions. Arch Intern Med. 1994;154(15):1721–1729.
- , , , , , . Preparing patients and caregivers to participate in care delivered across settings: the Care Transitions Intervention. J Am Geriatr Soc. 2004;52(11):1817–1825.
- , , , et al. Effect of a nurse team coordinator on outcomes for hospitalized medicine patients. Am J Med. 2005;118(10):1148–1153.
- , , , et al. Problems after discharge and understanding of communication with their primary care physicians among hospitalized seniors: a mixed methods study. J Hosp Med. 2010;5(7):385–391.
- , . Hospital readmissions in the Medicare population. N Engl J Med. 1984;311(21):1349–1353.
- , , , , . Development of a brief test to measure functional health literacy. Patient Educ Couns. 1999;38(1):33–42.
- , , , , , . Relationship of Health Literacy to Intentional and Unintentional Non‐Adherence of Hospital Discharge Medications. J Gen Intern Med. 2012;27(2):173–178.
- , , , et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157(1):99–104.
- . College men's health: an overview and a call to action. J Am Coll Health. 1998;46(6):279–290.
- Gender and the Social Construction of Illness. Thousand Oaks, CA: Sage; 1997.
- Inequalities in Health: The Black Report and the Health Divide. London, UK: Penguin; 1988.
- , , , . Decision making process in people with symptoms of acute myocardial infarction: qualitative study. BMJ. 2002;332:1006–1017.
- Centers for Medicare and Medicaid Services. Transitional Care Management Services. Available at: http://www.cms.gov/Medicare/Medicare‐Fee‐for‐Service‐Payment/PhysicianFeeSched/Downloads/FAQ‐TCMS.pdf. Accessed June 28, 2013.
© 2013 Society of Hospital Medicine
Studying Documentation
In 1968, Weed highlighted the importance of medical documentation when he proposed a single format for notes.[1, 2] Since then, sweeping changes in the technology, the purposes, and the requirements of clinical record keeping have encouraged steady growth of a literature devoted to the chart. Specifically, over the past half century, computers, lawsuits, regulations, and the use of documentation as a tool of billing have all contributed to the transformation of hospital records. In addition, mounting pressure to shorten inpatient stays, the vastly increased complexity of care, and a growing number of diagnostic possibilities have combined to make medical documentation far more prolific and far less leisurely. All these changes have stimulated a boom in documentation research coinciding, productively, with an era of rapid advances in the conduct of clinical trials and statistical rigor. However, in important respects research into medical documentation today is not asking the right questions, either in the formulation of hypotheses or in the choice of methodology. Forms of clinical communication that do not involve order sets or notes are widespread, growing in sophistication, and increasingly relevant to new concepts of healthcare as a team enterprise; but documentation research has not embraced this development. At the same time, methodologically, the field suffers from a persistent professional bias in the choice of research outcomes, a bias that limits the interpretation of results by neglecting what happens to the patient.
In assessing the chart as a communication device and the effect of changes in documentation, it is increasingly necessary to study direct interpersonal communication as an alternative and partner to writing notes. In particular, 3 recent developments in healthcare emphasize the importance of broadening our concepts of clinical communication. First, the need for discussion in the medical record has become less pressing because of technical improvements in person‐to‐person communication. Second, the electronic health record, by creating discipline‐defined chart views, has helped equalize the stature of different healthcare disciplines but also Balkanized the chart, making direct interdisciplinary communication more necessary. Third, changes in reimbursement are redefining medical goals in such a way that only teams of healthcare providers in close and constant personal communication can achieve them.
Rapid adoption of electronic health records has encouraged researchers studying documentation or information technology to focus on computer formats as defining the range of all possible communication strategies. And certainly there is a broad range of formats: electronic progress notes may be free text or multiple choice, typed or dictated, copy forwarded or composed daily, institutionally templated or self‐templated, furnished with or free from prompts and pop‐ups. However, it is not only, and perhaps not even principally, the electronic record that has changed how clinicians communicate with each other. The technology of discussion over the last 2 decades has become instant, utterly mobile, device independent, and capable of connecting all the patient's caregivers at once to each other and to the medical record in text, picture, and sound. That the same communications upheaval has visited practically every other aspect of our lives diminishes perhaps the visibility of this new virtual team in healthcare but not its importance.
The electronic record certainly plays a role in facilitating communication, through simultaneous chart access and in many other ways, but even more significant is the effect that computerization has had on equalizing the roles of different disciplines and by doing so in fragmenting the medical record. A computerized record expands and reorganizes the chart, changing it from a single authoritative book read by all to an almost limitless array of chart views, each read by some. All viewers (patient, clinician or researcher, administrator, reviewer or coder) can, with equal claim to consulting the chart, categorize, compare, combine, and format data elements from 1 or many encounters, whether inpatient or ambulatory. Typically, an electronic item of patient information may have several authors and uses but has no owner. Data are entered by protocol and in different guises into many aspects of patient care as components of notes, flow sheets, summaries, pop‐ups, and order sets unique to each of a number of disciplines. As the electronic record equalizes but also separates members of the healthcare team, interdisciplinary personal communication becomes more, not less, important.
Recent and impending reimbursement reform proves also to be a means of democratizing medical care and enforcing better interdisciplinary communication. The basis for hospital reimbursement has evolved over decades from day rates to payments for specific diseases, a system under which profit margins are in theory determined by the interdisciplinary efficiency with which diseases are managed by all care givers and the accuracy with which that management is documented. The next, seemingly inexorable, step in the evolution of reimbursement will result in further democratization of care givers: a single combined disease episode payment will be divided among all those involved in a course of treatment that may span many months and require many disciplines and many types of intervention. Payment reform makes the success of a visiting nurse as important to the net reimbursement of a disease episode as the success of an orthopedic surgeon; for if the visiting nurse does not do well the patient will be readmitted or require more office services. In this sense, payment reform, like the electronic record, tends both to equalize the importance of different healthcare roles and to require their enhanced communication.
As these changes in technology and reimbursement evolve, the study of medical documentation must increasingly address medical communication more generally. It is entirely possible, for example, that an individual daily progress note, whose preparation consumes so many hours and removes caretakers from patients, will no longer serve any demonstrable purpose.[3, 4] It may be that consensus summaries will prove more useful in clarifying one's own thinking and incorporating that of others than will a daily, solo chart soliloquy in free or imported text. It is conceivable that contrasting views will be best presented not as a debate in the progress notes but as a plan mutually agreed upon earlier in the decision‐making process. These are the kind of broader questions that investigators in medical documentation should be pursuing.
Another problem in studies of documentation is a pervasive professional bias in the choice of end points. Studies tend to evaluate documentary practices not by their effect on patients but by their impact on physicians or nurses. Success is measured by clinician satisfaction, percent adoption, and note length or timing; note quality is judged using a checklist derived from professional surveys.[5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15] End points like these will often make 1 document look better than another in a results section, but it is the relation between communication strategies and healthcare outcomes that determines whether 1 approach or another is of benefit to the patient.
For example, an important current debate is whether free text adds essential nuance to a note or is simply nostalgia, a relic of the 3‐ring binder.[16, 17, 18] This debate can be resolved convincingly only if improvement with the use or abolition of free text is measured in terms of patient outcomes or resource consumption. Again, if it is important to know whether progress notes of a particular length or structure create less handover confusion, then changes in medical error rates is a more persuasive way to evaluate this issue than a change in physician opinion. It may be a good question whether briefer notes will free nurses and doctors to spend more time at the bedside, but along with recording bedside time that study should also measure improvement in reacting to important changes of clinical status. With today's technology, group phone discussions could perhaps successfully replace examining each other's notes, but the measure of success should be improved hospital efficiency or a decline in errors and readmissions.
The questions we ask in our research today create the treatments and policies of tomorrow. Our studies must address communications in a larger sense, must encompass all the settings in which an episode of care occurs, and must focus on patient outcomes and use of resources. The measured end points of an intervention should of course be sensitive to the particular setting where the intervention takes place, or else small and location‐specific gains will be missed. However, real health effects and robust measures of efficiency must take the place of word counts, inclusion checklists, and clinician adoption or satisfaction in the design of documentation studies.
A great national experiment is underway involving the deployment of information technology, the expansion and empowerment of healthcare teams, and the retargeting of economic incentives. The experimental hypothesis is that technology will increase medical efficiency and will benefit patient well‐being only if these are in fact the purposes, and if teamwork is the principal means, of providing medical care. We should seize this time of change as an opportunity to measure and demonstrably improve the contribution of medical documentation and communication to the efficient and long‐term remission of disease.
- . Medical records that guide and teach. N Engl J Med. 1968;278(12):593–600.
- . Medical records that guide and teach. N Engl J Med. 1968;278(12):652–257.
- , , , . Use of electronic clinical documentation: time spent and team interactions. J Am Med Inform Assoc. 2011;18(2):112–117.
- , , , , , . The influence of integrated electronic medical records and computerized nursing notes on nurses' time spent in documentation. Comput Inform Nurs. 2012;30(6):287–292.
- , , , , . The hybrid progress note: semiautomating daily progress notes to achieve high‐quality documentation and improve provider efficiency. Am J Med Qual. 2013;28(1):25–32.
- , , , . Preliminary development of the physician documentation quality instrument. J Am Med Inform Assoc. 2008;15(4):534–541.
- , , , , . Evaluation of residents' delivery notes after a simulated shoulder dystocia. Obstet Gynecol. 2004;104(4):667–670.
- , , , , , . Validity evidence for a patient note scoring rubric based on the new patient note format of the United States Medical Licensing Examination. Acad Med. 2013;88(10):1552–1557.
- , , , . Quality of outpatient clinical notes: a stakeholder definition derived through qualitative research. BMC Health Serv Res. 2012;12:407.
- , , . Definition, structure, content, use and impacts of electronic health records: a review of the research literature. Int J Med Inform. 2008;77(5):291–304.
- , , , et al. Randomised trial comparing the recording ability of a novel, electronic emergency documentation system with the AHA paper cardiac arrest record [published online ahead of print July 29, 2013]. Emerg Med J. doi: 10.1136/emermed‐2013‐202512.
- , , , et al. Generating clinical notes for electronic health record systems. Appl Clin Inform. 2010;1(3):232–243.
- , , . The effects of EMR deployment on doctors' work practices: a qualitative study in the emergency department of a teaching hospital. Int J Med Inform. 2012;81(3):204–217.
- , , , , . Comparison of handheld computer‐assisted and conventional paper chart documentation of medical records. A randomized, controlled trial. J Bone Joint Surg Am. 2004;86A(3):553–560.
- , , , , . Assessing quality and efficiency of discharge summaries. Am J Med Qual. 2005;20(6):337–343.
- , , , , , . Physicians' attitudes towards copy and pasting in electronic note writing. J Gen Intern Med. 2009;24(1):63–68.
- , , , . Association of medical directors of information systems consensus on inpatient electronic health record documentation. Appl Clin Inform. 2013;4(2):293–303.
- , , . Method of electronic health record documentation and quality of primary care. Am Med Inform Assoc. 2012;19(6):1019–1024.
In 1968, Weed highlighted the importance of medical documentation when he proposed a single format for notes.[1, 2] Since then, sweeping changes in the technology, the purposes, and the requirements of clinical record keeping have encouraged steady growth of a literature devoted to the chart. Specifically, over the past half century, computers, lawsuits, regulations, and the use of documentation as a tool of billing have all contributed to the transformation of hospital records. In addition, mounting pressure to shorten inpatient stays, the vastly increased complexity of care, and a growing number of diagnostic possibilities have combined to make medical documentation far more prolific and far less leisurely. All these changes have stimulated a boom in documentation research coinciding, productively, with an era of rapid advances in the conduct of clinical trials and statistical rigor. However, in important respects research into medical documentation today is not asking the right questions, either in the formulation of hypotheses or in the choice of methodology. Forms of clinical communication that do not involve order sets or notes are widespread, growing in sophistication, and increasingly relevant to new concepts of healthcare as a team enterprise; but documentation research has not embraced this development. At the same time, methodologically, the field suffers from a persistent professional bias in the choice of research outcomes, a bias that limits the interpretation of results by neglecting what happens to the patient.
In assessing the chart as a communication device and the effect of changes in documentation, it is increasingly necessary to study direct interpersonal communication as an alternative and partner to writing notes. In particular, 3 recent developments in healthcare emphasize the importance of broadening our concepts of clinical communication. First, the need for discussion in the medical record has become less pressing because of technical improvements in person‐to‐person communication. Second, the electronic health record, by creating discipline‐defined chart views, has helped equalize the stature of different healthcare disciplines but also Balkanized the chart, making direct interdisciplinary communication more necessary. Third, changes in reimbursement are redefining medical goals in such a way that only teams of healthcare providers in close and constant personal communication can achieve them.
Rapid adoption of electronic health records has encouraged researchers studying documentation or information technology to focus on computer formats as defining the range of all possible communication strategies. And certainly there is a broad range of formats: electronic progress notes may be free text or multiple choice, typed or dictated, copy forwarded or composed daily, institutionally templated or self‐templated, furnished with or free from prompts and pop‐ups. However, it is not only, and perhaps not even principally, the electronic record that has changed how clinicians communicate with each other. The technology of discussion over the last 2 decades has become instant, utterly mobile, device independent, and capable of connecting all the patient's caregivers at once to each other and to the medical record in text, picture, and sound. That the same communications upheaval has visited practically every other aspect of our lives diminishes perhaps the visibility of this new virtual team in healthcare but not its importance.
The electronic record certainly plays a role in facilitating communication, through simultaneous chart access and in many other ways, but even more significant is the effect that computerization has had on equalizing the roles of different disciplines and by doing so in fragmenting the medical record. A computerized record expands and reorganizes the chart, changing it from a single authoritative book read by all to an almost limitless array of chart views, each read by some. All viewers (patient, clinician or researcher, administrator, reviewer or coder) can, with equal claim to consulting the chart, categorize, compare, combine, and format data elements from 1 or many encounters, whether inpatient or ambulatory. Typically, an electronic item of patient information may have several authors and uses but has no owner. Data are entered by protocol and in different guises into many aspects of patient care as components of notes, flow sheets, summaries, pop‐ups, and order sets unique to each of a number of disciplines. As the electronic record equalizes but also separates members of the healthcare team, interdisciplinary personal communication becomes more, not less, important.
Recent and impending reimbursement reform proves also to be a means of democratizing medical care and enforcing better interdisciplinary communication. The basis for hospital reimbursement has evolved over decades from day rates to payments for specific diseases, a system under which profit margins are in theory determined by the interdisciplinary efficiency with which diseases are managed by all care givers and the accuracy with which that management is documented. The next, seemingly inexorable, step in the evolution of reimbursement will result in further democratization of care givers: a single combined disease episode payment will be divided among all those involved in a course of treatment that may span many months and require many disciplines and many types of intervention. Payment reform makes the success of a visiting nurse as important to the net reimbursement of a disease episode as the success of an orthopedic surgeon; for if the visiting nurse does not do well the patient will be readmitted or require more office services. In this sense, payment reform, like the electronic record, tends both to equalize the importance of different healthcare roles and to require their enhanced communication.
As these changes in technology and reimbursement evolve, the study of medical documentation must increasingly address medical communication more generally. It is entirely possible, for example, that an individual daily progress note, whose preparation consumes so many hours and removes caretakers from patients, will no longer serve any demonstrable purpose.[3, 4] It may be that consensus summaries will prove more useful in clarifying one's own thinking and incorporating that of others than will a daily, solo chart soliloquy in free or imported text. It is conceivable that contrasting views will be best presented not as a debate in the progress notes but as a plan mutually agreed upon earlier in the decision‐making process. These are the kind of broader questions that investigators in medical documentation should be pursuing.
Another problem in studies of documentation is a pervasive professional bias in the choice of end points. Studies tend to evaluate documentary practices not by their effect on patients but by their impact on physicians or nurses. Success is measured by clinician satisfaction, percent adoption, and note length or timing; note quality is judged using a checklist derived from professional surveys.[5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15] End points like these will often make 1 document look better than another in a results section, but it is the relation between communication strategies and healthcare outcomes that determines whether 1 approach or another is of benefit to the patient.
For example, an important current debate is whether free text adds essential nuance to a note or is simply nostalgia, a relic of the 3‐ring binder.[16, 17, 18] This debate can be resolved convincingly only if improvement with the use or abolition of free text is measured in terms of patient outcomes or resource consumption. Again, if it is important to know whether progress notes of a particular length or structure create less handover confusion, then changes in medical error rates is a more persuasive way to evaluate this issue than a change in physician opinion. It may be a good question whether briefer notes will free nurses and doctors to spend more time at the bedside, but along with recording bedside time that study should also measure improvement in reacting to important changes of clinical status. With today's technology, group phone discussions could perhaps successfully replace examining each other's notes, but the measure of success should be improved hospital efficiency or a decline in errors and readmissions.
The questions we ask in our research today create the treatments and policies of tomorrow. Our studies must address communications in a larger sense, must encompass all the settings in which an episode of care occurs, and must focus on patient outcomes and use of resources. The measured end points of an intervention should of course be sensitive to the particular setting where the intervention takes place, or else small and location‐specific gains will be missed. However, real health effects and robust measures of efficiency must take the place of word counts, inclusion checklists, and clinician adoption or satisfaction in the design of documentation studies.
A great national experiment is underway involving the deployment of information technology, the expansion and empowerment of healthcare teams, and the retargeting of economic incentives. The experimental hypothesis is that technology will increase medical efficiency and will benefit patient well‐being only if these are in fact the purposes, and if teamwork is the principal means, of providing medical care. We should seize this time of change as an opportunity to measure and demonstrably improve the contribution of medical documentation and communication to the efficient and long‐term remission of disease.
In 1968, Weed highlighted the importance of medical documentation when he proposed a single format for notes.[1, 2] Since then, sweeping changes in the technology, the purposes, and the requirements of clinical record keeping have encouraged steady growth of a literature devoted to the chart. Specifically, over the past half century, computers, lawsuits, regulations, and the use of documentation as a tool of billing have all contributed to the transformation of hospital records. In addition, mounting pressure to shorten inpatient stays, the vastly increased complexity of care, and a growing number of diagnostic possibilities have combined to make medical documentation far more prolific and far less leisurely. All these changes have stimulated a boom in documentation research coinciding, productively, with an era of rapid advances in the conduct of clinical trials and statistical rigor. However, in important respects research into medical documentation today is not asking the right questions, either in the formulation of hypotheses or in the choice of methodology. Forms of clinical communication that do not involve order sets or notes are widespread, growing in sophistication, and increasingly relevant to new concepts of healthcare as a team enterprise; but documentation research has not embraced this development. At the same time, methodologically, the field suffers from a persistent professional bias in the choice of research outcomes, a bias that limits the interpretation of results by neglecting what happens to the patient.
In assessing the chart as a communication device and the effect of changes in documentation, it is increasingly necessary to study direct interpersonal communication as an alternative and partner to writing notes. In particular, 3 recent developments in healthcare emphasize the importance of broadening our concepts of clinical communication. First, the need for discussion in the medical record has become less pressing because of technical improvements in person‐to‐person communication. Second, the electronic health record, by creating discipline‐defined chart views, has helped equalize the stature of different healthcare disciplines but also Balkanized the chart, making direct interdisciplinary communication more necessary. Third, changes in reimbursement are redefining medical goals in such a way that only teams of healthcare providers in close and constant personal communication can achieve them.
Rapid adoption of electronic health records has encouraged researchers studying documentation or information technology to focus on computer formats as defining the range of all possible communication strategies. And certainly there is a broad range of formats: electronic progress notes may be free text or multiple choice, typed or dictated, copy forwarded or composed daily, institutionally templated or self‐templated, furnished with or free from prompts and pop‐ups. However, it is not only, and perhaps not even principally, the electronic record that has changed how clinicians communicate with each other. The technology of discussion over the last 2 decades has become instant, utterly mobile, device independent, and capable of connecting all the patient's caregivers at once to each other and to the medical record in text, picture, and sound. That the same communications upheaval has visited practically every other aspect of our lives diminishes perhaps the visibility of this new virtual team in healthcare but not its importance.
The electronic record certainly plays a role in facilitating communication, through simultaneous chart access and in many other ways, but even more significant is the effect that computerization has had on equalizing the roles of different disciplines and by doing so in fragmenting the medical record. A computerized record expands and reorganizes the chart, changing it from a single authoritative book read by all to an almost limitless array of chart views, each read by some. All viewers (patient, clinician or researcher, administrator, reviewer or coder) can, with equal claim to consulting the chart, categorize, compare, combine, and format data elements from 1 or many encounters, whether inpatient or ambulatory. Typically, an electronic item of patient information may have several authors and uses but has no owner. Data are entered by protocol and in different guises into many aspects of patient care as components of notes, flow sheets, summaries, pop‐ups, and order sets unique to each of a number of disciplines. As the electronic record equalizes but also separates members of the healthcare team, interdisciplinary personal communication becomes more, not less, important.
Recent and impending reimbursement reform proves also to be a means of democratizing medical care and enforcing better interdisciplinary communication. The basis for hospital reimbursement has evolved over decades from day rates to payments for specific diseases, a system under which profit margins are in theory determined by the interdisciplinary efficiency with which diseases are managed by all care givers and the accuracy with which that management is documented. The next, seemingly inexorable, step in the evolution of reimbursement will result in further democratization of care givers: a single combined disease episode payment will be divided among all those involved in a course of treatment that may span many months and require many disciplines and many types of intervention. Payment reform makes the success of a visiting nurse as important to the net reimbursement of a disease episode as the success of an orthopedic surgeon; for if the visiting nurse does not do well the patient will be readmitted or require more office services. In this sense, payment reform, like the electronic record, tends both to equalize the importance of different healthcare roles and to require their enhanced communication.
As these changes in technology and reimbursement evolve, the study of medical documentation must increasingly address medical communication more generally. It is entirely possible, for example, that an individual daily progress note, whose preparation consumes so many hours and removes caretakers from patients, will no longer serve any demonstrable purpose.[3, 4] It may be that consensus summaries will prove more useful in clarifying one's own thinking and incorporating that of others than will a daily, solo chart soliloquy in free or imported text. It is conceivable that contrasting views will be best presented not as a debate in the progress notes but as a plan mutually agreed upon earlier in the decision‐making process. These are the kind of broader questions that investigators in medical documentation should be pursuing.
Another problem in studies of documentation is a pervasive professional bias in the choice of end points. Studies tend to evaluate documentary practices not by their effect on patients but by their impact on physicians or nurses. Success is measured by clinician satisfaction, percent adoption, and note length or timing; note quality is judged using a checklist derived from professional surveys.[5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15] End points like these will often make 1 document look better than another in a results section, but it is the relation between communication strategies and healthcare outcomes that determines whether 1 approach or another is of benefit to the patient.
For example, an important current debate is whether free text adds essential nuance to a note or is simply nostalgia, a relic of the 3‐ring binder.[16, 17, 18] This debate can be resolved convincingly only if improvement with the use or abolition of free text is measured in terms of patient outcomes or resource consumption. Again, if it is important to know whether progress notes of a particular length or structure create less handover confusion, then changes in medical error rates is a more persuasive way to evaluate this issue than a change in physician opinion. It may be a good question whether briefer notes will free nurses and doctors to spend more time at the bedside, but along with recording bedside time that study should also measure improvement in reacting to important changes of clinical status. With today's technology, group phone discussions could perhaps successfully replace examining each other's notes, but the measure of success should be improved hospital efficiency or a decline in errors and readmissions.
The questions we ask in our research today create the treatments and policies of tomorrow. Our studies must address communications in a larger sense, must encompass all the settings in which an episode of care occurs, and must focus on patient outcomes and use of resources. The measured end points of an intervention should of course be sensitive to the particular setting where the intervention takes place, or else small and location‐specific gains will be missed. However, real health effects and robust measures of efficiency must take the place of word counts, inclusion checklists, and clinician adoption or satisfaction in the design of documentation studies.
A great national experiment is underway involving the deployment of information technology, the expansion and empowerment of healthcare teams, and the retargeting of economic incentives. The experimental hypothesis is that technology will increase medical efficiency and will benefit patient well‐being only if these are in fact the purposes, and if teamwork is the principal means, of providing medical care. We should seize this time of change as an opportunity to measure and demonstrably improve the contribution of medical documentation and communication to the efficient and long‐term remission of disease.
- . Medical records that guide and teach. N Engl J Med. 1968;278(12):593–600.
- . Medical records that guide and teach. N Engl J Med. 1968;278(12):652–257.
- , , , . Use of electronic clinical documentation: time spent and team interactions. J Am Med Inform Assoc. 2011;18(2):112–117.
- , , , , , . The influence of integrated electronic medical records and computerized nursing notes on nurses' time spent in documentation. Comput Inform Nurs. 2012;30(6):287–292.
- , , , , . The hybrid progress note: semiautomating daily progress notes to achieve high‐quality documentation and improve provider efficiency. Am J Med Qual. 2013;28(1):25–32.
- , , , . Preliminary development of the physician documentation quality instrument. J Am Med Inform Assoc. 2008;15(4):534–541.
- , , , , . Evaluation of residents' delivery notes after a simulated shoulder dystocia. Obstet Gynecol. 2004;104(4):667–670.
- , , , , , . Validity evidence for a patient note scoring rubric based on the new patient note format of the United States Medical Licensing Examination. Acad Med. 2013;88(10):1552–1557.
- , , , . Quality of outpatient clinical notes: a stakeholder definition derived through qualitative research. BMC Health Serv Res. 2012;12:407.
- , , . Definition, structure, content, use and impacts of electronic health records: a review of the research literature. Int J Med Inform. 2008;77(5):291–304.
- , , , et al. Randomised trial comparing the recording ability of a novel, electronic emergency documentation system with the AHA paper cardiac arrest record [published online ahead of print July 29, 2013]. Emerg Med J. doi: 10.1136/emermed‐2013‐202512.
- , , , et al. Generating clinical notes for electronic health record systems. Appl Clin Inform. 2010;1(3):232–243.
- , , . The effects of EMR deployment on doctors' work practices: a qualitative study in the emergency department of a teaching hospital. Int J Med Inform. 2012;81(3):204–217.
- , , , , . Comparison of handheld computer‐assisted and conventional paper chart documentation of medical records. A randomized, controlled trial. J Bone Joint Surg Am. 2004;86A(3):553–560.
- , , , , . Assessing quality and efficiency of discharge summaries. Am J Med Qual. 2005;20(6):337–343.
- , , , , , . Physicians' attitudes towards copy and pasting in electronic note writing. J Gen Intern Med. 2009;24(1):63–68.
- , , , . Association of medical directors of information systems consensus on inpatient electronic health record documentation. Appl Clin Inform. 2013;4(2):293–303.
- , , . Method of electronic health record documentation and quality of primary care. Am Med Inform Assoc. 2012;19(6):1019–1024.
- . Medical records that guide and teach. N Engl J Med. 1968;278(12):593–600.
- . Medical records that guide and teach. N Engl J Med. 1968;278(12):652–257.
- , , , . Use of electronic clinical documentation: time spent and team interactions. J Am Med Inform Assoc. 2011;18(2):112–117.
- , , , , , . The influence of integrated electronic medical records and computerized nursing notes on nurses' time spent in documentation. Comput Inform Nurs. 2012;30(6):287–292.
- , , , , . The hybrid progress note: semiautomating daily progress notes to achieve high‐quality documentation and improve provider efficiency. Am J Med Qual. 2013;28(1):25–32.
- , , , . Preliminary development of the physician documentation quality instrument. J Am Med Inform Assoc. 2008;15(4):534–541.
- , , , , . Evaluation of residents' delivery notes after a simulated shoulder dystocia. Obstet Gynecol. 2004;104(4):667–670.
- , , , , , . Validity evidence for a patient note scoring rubric based on the new patient note format of the United States Medical Licensing Examination. Acad Med. 2013;88(10):1552–1557.
- , , , . Quality of outpatient clinical notes: a stakeholder definition derived through qualitative research. BMC Health Serv Res. 2012;12:407.
- , , . Definition, structure, content, use and impacts of electronic health records: a review of the research literature. Int J Med Inform. 2008;77(5):291–304.
- , , , et al. Randomised trial comparing the recording ability of a novel, electronic emergency documentation system with the AHA paper cardiac arrest record [published online ahead of print July 29, 2013]. Emerg Med J. doi: 10.1136/emermed‐2013‐202512.
- , , , et al. Generating clinical notes for electronic health record systems. Appl Clin Inform. 2010;1(3):232–243.
- , , . The effects of EMR deployment on doctors' work practices: a qualitative study in the emergency department of a teaching hospital. Int J Med Inform. 2012;81(3):204–217.
- , , , , . Comparison of handheld computer‐assisted and conventional paper chart documentation of medical records. A randomized, controlled trial. J Bone Joint Surg Am. 2004;86A(3):553–560.
- , , , , . Assessing quality and efficiency of discharge summaries. Am J Med Qual. 2005;20(6):337–343.
- , , , , , . Physicians' attitudes towards copy and pasting in electronic note writing. J Gen Intern Med. 2009;24(1):63–68.
- , , , . Association of medical directors of information systems consensus on inpatient electronic health record documentation. Appl Clin Inform. 2013;4(2):293–303.
- , , . Method of electronic health record documentation and quality of primary care. Am Med Inform Assoc. 2012;19(6):1019–1024.